<!DOCTYPE html><html lang="zh-TW"><head><title>How I treat refractory CRS and ICANS after CAR T-cell therapy</title><meta property="og:title" content="How I treat refractory CRS and ICANS after CAR T-cell therapy"><meta name="author" content="Hsieh-Ting Lin"><meta property="article:author" content="Hsieh-Ting Lin"><meta charset="UTF-8"><meta name="viewport" content="width=device-width,height=device-height,initial-scale=1.0"><meta name="apple-mobile-web-app-capable" content="yes"><meta http-equiv="X-UA-Compatible" content="ie=edge"><meta property="og:type" content="website"><meta name="twitter:card" content="summary"><style>@media screen{body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button{-webkit-tap-highlight-color:transparent;-webkit-appearance:none;appearance:none;background-color:initial;border:0;color:inherit;cursor:pointer;font-size:inherit;opacity:.8;outline:none;padding:0;transition:opacity .2s linear}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:disabled,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:disabled,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:disabled,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:disabled{cursor:not-allowed;opacity:.15!important}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:hover,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:hover,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:hover,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:hover{opacity:1}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:active,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:active,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:hover:active,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:hover:active{opacity:.6}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:not(:disabled),body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button:hover:not(:disabled),body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button:hover:not(:disabled),body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button:hover:not(:disabled){transition:none}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev],body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button.bespoke-marp-presenter-info-page-prev{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNNjggOTAgMjggNTBsNDAtNDAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button.bespoke-marp-presenter-info-page-next{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJtMzIgOTAgNDAtNDAtNDAtNDAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen]{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48ZGVmcz48c3R5bGU+LmF7ZmlsbDpub25lO3N0cm9rZTojZmZmO3N0cm9rZS1saW5lY2FwOnJvdW5kO3N0cm9rZS1saW5lam9pbjpyb3VuZDtzdHJva2Utd2lkdGg6NXB4fTwvc3R5bGU+PC9kZWZzPjxyZWN0IHdpZHRoPSI4MCIgaGVpZ2h0PSI2MCIgeD0iMTAiIHk9IjIwIiBjbGFzcz0iYSIgcng9IjUuNjciLz48cGF0aCBkPSJNNDAgNzBIMjBWNTBtMjAgMEwyMCA3MG00MC00MGgyMHYyMG0tMjAgMCAyMC0yMCIgY2xhc3M9ImEiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button.exit[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button.exit[data-bespoke-marp-osc=fullscreen]{background-image:url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48ZGVmcz48c3R5bGU+LmF7ZmlsbDpub25lO3N0cm9rZTojZmZmO3N0cm9rZS1saW5lY2FwOnJvdW5kO3N0cm9rZS1saW5lam9pbjpyb3VuZDtzdHJva2Utd2lkdGg6NXB4fTwvc3R5bGU+PC9kZWZzPjxyZWN0IHdpZHRoPSI4MCIgaGVpZ2h0PSI2MCIgeD0iMTAiIHk9IjIwIiBjbGFzcz0iYSIgcng9IjUuNjciLz48cGF0aCBkPSJNMjAgNTBoMjB2MjBtLTIwIDAgMjAtMjBtNDAgMEg2MFYzMG0yMCAwTDYwIDUwIiBjbGFzcz0iYSIvPjwvc3ZnPg==")}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter]{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNODcuOCA0Ny41Qzg5IDUwIDg3LjcgNTIgODUgNTJIMzVhOC43IDguNyAwIDAgMS03LjItNC41bC0xNS42LTMxQzExIDE0IDEyLjIgMTIgMTUgMTJoNTBhOC44IDguOCAwIDAgMSA3LjIgNC41ek02MCA1MnYzNm0tMTAgMGgyME00NSA0MmgyMCIvPjwvc3ZnPg==") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button.bespoke-marp-presenter-note-bigger{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNMTIgNTBoODBNNTIgOTBWMTAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button.bespoke-marp-presenter-note-smaller{background:#0000 url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAxMDAgMTAwIj48cGF0aCBmaWxsPSJub25lIiBzdHJva2U9IiNmZmYiIHN0cm9rZS1saW5lY2FwPSJyb3VuZCIgc3Ryb2tlLWxpbmVqb2luPSJyb3VuZCIgc3Ryb2tlLXdpZHRoPSI1IiBkPSJNMTIgNTBoODAiLz48L3N2Zz4=") no-repeat 50%;background-size:contain;overflow:hidden;text-indent:100%;white-space:nowrap}}@keyframes __bespoke_marp_transition_reduced_outgoing__{0%{opacity:1}to{opacity:0}}@keyframes __bespoke_marp_transition_reduced_incoming__{0%{mix-blend-mode:plus-lighter;opacity:0}to{mix-blend-mode:plus-lighter;opacity:1}}.bespoke-marp-note,.bespoke-marp-osc,.bespoke-progress-parent{display:none;transition:none}@media screen{::view-transition-group(*){animation-duration:var(--marp-bespoke-transition-animation-duration,.5s);animation-timing-function:ease}::view-transition-new(*),::view-transition-old(*){animation-delay:0s;animation-direction:var(--marp-bespoke-transition-animation-direction,normal);animation-duration:var(--marp-bespoke-transition-animation-duration,.5s);animation-fill-mode:both;animation-name:var(--marp-bespoke-transition-animation-name,var(--marp-bespoke-transition-animation-name-fallback,__bespoke_marp_transition_no_animation__));mix-blend-mode:normal}::view-transition-old(*){--marp-bespoke-transition-animation-name-fallback:__bespoke_marp_transition_reduced_outgoing__;animation-timing-function:ease}::view-transition-new(*){--marp-bespoke-transition-animation-name-fallback:__bespoke_marp_transition_reduced_incoming__;animation-timing-function:ease}::view-transition-new(root),::view-transition-old(root){animation-timing-function:linear}::view-transition-new(__bespoke_marp_transition_osc__),::view-transition-old(__bespoke_marp_transition_osc__){animation-duration:0s!important;animation-name:__bespoke_marp_transition_osc__!important}::view-transition-new(__bespoke_marp_transition_osc__){opacity:0!important}.bespoke-marp-transition-warming-up::view-transition-group(*),.bespoke-marp-transition-warming-up::view-transition-new(*),.bespoke-marp-transition-warming-up::view-transition-old(*){animation-play-state:paused!important}body,html{height:100%;margin:0}body{background:#000;overflow:hidden}svg.bespoke-marp-slide{content-visibility:hidden;opacity:0;pointer-events:none;z-index:-1}svg.bespoke-marp-slide:not(.bespoke-marp-active) *{view-transition-name:none!important}svg.bespoke-marp-slide.bespoke-marp-active{content-visibility:visible;opacity:1;pointer-events:auto;z-index:0}svg.bespoke-marp-slide.bespoke-marp-active.bespoke-marp-active-ready *{animation-name:__bespoke_marp__!important}@supports not (content-visibility:hidden){svg.bespoke-marp-slide[data-bespoke-marp-load=hideable]{display:none}svg.bespoke-marp-slide[data-bespoke-marp-load=hideable].bespoke-marp-active{display:block}}}@media screen and (prefers-reduced-motion:reduce){svg.bespoke-marp-slide *{view-transition-name:none!important}}@media screen{[data-bespoke-marp-fragment=inactive]{visibility:hidden}body[data-bespoke-view=""] .bespoke-marp-parent,body[data-bespoke-view=next] .bespoke-marp-parent{inset:0;position:absolute}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc{view-transition-name:__bespoke_marp_transition_osc__;background:#000000a6;border-radius:7px;bottom:50px;color:#fff;contain:paint;display:block;font-family:Helvetica,Arial,sans-serif;font-size:16px;left:50%;line-height:0;opacity:1;padding:12px;position:absolute;touch-action:manipulation;transform:translateX(-50%);transition:opacity .2s linear;-webkit-user-select:none;user-select:none;white-space:nowrap;will-change:transform;z-index:1}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>*,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>*{margin-left:6px}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>:first-child,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>:first-child{margin-left:0}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>span,body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>span{opacity:.8}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>span[data-bespoke-marp-osc=page],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>span[data-bespoke-marp-osc=page]{display:inline-block;min-width:140px;text-align:center}body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter],body[data-bespoke-view=""] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=fullscreen],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=next],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=presenter],body[data-bespoke-view=next] .bespoke-marp-parent>.bespoke-marp-osc>button[data-bespoke-marp-osc=prev]{height:32px;line-height:32px;width:32px}body[data-bespoke-view=""] .bespoke-marp-parent.bespoke-marp-inactive,body[data-bespoke-view=next] .bespoke-marp-parent.bespoke-marp-inactive{cursor:none}body[data-bespoke-view=""] .bespoke-marp-parent.bespoke-marp-inactive>.bespoke-marp-osc,body[data-bespoke-view=next] .bespoke-marp-parent.bespoke-marp-inactive>.bespoke-marp-osc{opacity:0;pointer-events:none}body[data-bespoke-view=""] svg.bespoke-marp-slide,body[data-bespoke-view=next] svg.bespoke-marp-slide{height:100%;left:0;position:absolute;top:0;width:100%}body[data-bespoke-view=""] .bespoke-progress-parent{background:#222;display:flex;height:5px;width:100%}body[data-bespoke-view=""] .bespoke-progress-parent+.bespoke-marp-parent{top:5px}body[data-bespoke-view=""] .bespoke-progress-parent .bespoke-progress-bar{background:#0288d1;flex:0 0 0;transition:flex-basis .2s cubic-bezier(0,1,1,1)}body[data-bespoke-view=next]{background:#0000}body[data-bespoke-view=presenter]{background:#161616}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container{display:grid;font-family:Helvetica,Arial,sans-serif;grid-template:"current dragbar next" minmax(140px,1fr) "current dragbar note" 2fr "info    dragbar note" 3em;grid-template-columns:minmax(3px,var(--bespoke-marp-presenter-split-ratio,66%)) 0 minmax(3px,1fr);height:100%;left:0;position:absolute;top:0;width:100%}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-parent{grid-area:current;overflow:hidden;position:relative}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-parent svg.bespoke-marp-slide{height:calc(100% - 40px);left:20px;pointer-events:none;position:absolute;top:20px;-webkit-user-select:none;user-select:none;width:calc(100% - 40px)}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-parent svg.bespoke-marp-slide.bespoke-marp-active{filter:drop-shadow(0 3px 10px rgba(0,0,0,.5))}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-dragbar-container{background:#0288d1;cursor:col-resize;grid-area:dragbar;margin-left:-3px;opacity:0;position:relative;transition:opacity .4s linear .1s;width:6px;z-index:10}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-dragbar-container:hover{opacity:1}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-dragbar-container.active{opacity:1;transition-delay:0s}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-next-container{background:#222;cursor:pointer;display:none;grid-area:next;overflow:hidden;position:relative}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-next-container.active{display:block}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-next-container iframe.bespoke-marp-presenter-next{background:#0000;border:0;display:block;filter:drop-shadow(0 3px 10px rgba(0,0,0,.5));height:calc(100% - 40px);left:20px;pointer-events:none;position:absolute;top:20px;-webkit-user-select:none;user-select:none;width:calc(100% - 40px)}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container{background:#222;color:#eee;grid-area:note;position:relative;z-index:1}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container button{height:1.5em;line-height:1.5em;width:1.5em}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-wrapper{display:block;inset:0;position:absolute}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-buttons{background:#000000a6;border-radius:4px;bottom:0;display:flex;gap:4px;margin:12px;opacity:0;padding:6px;pointer-events:none;position:absolute;right:0;transition:opacity .2s linear}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-buttons:focus-within,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-presenter-note-wrapper:focus-within+.bespoke-marp-presenter-note-buttons,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container:hover .bespoke-marp-presenter-note-buttons{opacity:1;pointer-events:auto}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note{word-wrap:break-word;box-sizing:border-box;font-size:calc(1.1em*var(--bespoke-marp-note-font-scale, 1));height:calc(100% - 40px);margin:20px;overflow:auto;padding-right:3px;scrollbar-color:#eeeeee80 #0000;scrollbar-width:thin;white-space:pre-wrap;width:calc(100% - 40px)}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note::-webkit-scrollbar{width:6px}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note::-webkit-scrollbar-track{background:#0000}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note::-webkit-scrollbar-thumb{background:#eeeeee80;border-radius:6px}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note:empty{pointer-events:none}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note.active{display:block}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note p:first-child{margin-top:0}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-note-container .bespoke-marp-note p:last-child{margin-bottom:0}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container{align-items:center;box-sizing:border-box;color:#eee;display:flex;flex-wrap:nowrap;grid-area:info;justify-content:center;overflow:hidden;padding:0 10px}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-page,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-time,body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-timer{box-sizing:border-box;display:block;padding:0 10px;white-space:nowrap;width:100%}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container button{height:1.5em;line-height:1.5em;width:1.5em}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-page{order:2;text-align:center}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-page .bespoke-marp-presenter-info-page-text{display:inline-block;min-width:120px;text-align:center}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-time{color:#999;order:1;text-align:left}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-timer{color:#999;order:3;text-align:right}body[data-bespoke-view=presenter] .bespoke-marp-presenter-container .bespoke-marp-presenter-info-container .bespoke-marp-presenter-info-timer:hover{cursor:pointer}}@media print{.bespoke-marp-presenter-info-container,.bespoke-marp-presenter-next-container,.bespoke-marp-presenter-note-container{display:none}}</style><style>@charset "UTF-8";@import url('https://unpkg.com/markdown-it-admon/styles/admonition.css');@import url("https://fonts.googleapis.com/css2?family=Overpass+Mono:wght@400;500;600;700&display=swap");@import url("https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,500;0,600;0,700;0,800;1,500;1,600&display=swap");@import url('https://fonts.googleapis.com/css2?family=JetBrains+Mono:wght@400;600;800&display=swap');div#\:\$p>svg>foreignObject>section{width:1280px;height:720px;box-sizing:border-box;overflow:hidden;position:relative;scroll-snap-align:center center}div#\:\$p>svg>foreignObject>section:after{bottom:0;content:attr(data-marpit-pagination);padding:inherit;pointer-events:none;position:absolute;right:0}div#\:\$p>svg>foreignObject>section:not([data-marpit-pagination]):after{display:none}/* Normalization */div#\:\$p>svg>foreignObject>section :is(h1,marp-h1){font-size:2em;margin:0.67em 0}div#\:\$p>svg>foreignObject>section video::-webkit-media-controls{will-change:transform}@page{size:1280px 720px;margin:0}@media print{body,html{background-color:#fff;margin:0;page-break-inside:avoid;break-inside:avoid-page}div#\:\$p>svg>foreignObject>section{page-break-before:always;break-before:page}div#\:\$p>svg>foreignObject>section,div#\:\$p>svg>foreignObject>section *{-webkit-print-color-adjust:exact!important;animation-delay:0s!important;animation-duration:0s!important;color-adjust:exact!important;transition:none!important}div#\:\$p>svg[data-marpit-svg]{display:block;height:100vh;width:100vw}}div#\:\$p>svg>foreignObject>section img[data-marp-twemoji]{background:transparent;height:1em;margin:0 .05em 0 .1em;vertical-align:-.1em;width:1em}

/* @theme my-theme */
/*!
 *
 * @auto-scaling true
 * @size 4:3 960px 720px
 * @size 16:9 1280px 720px
 */div#\:\$p>svg>foreignObject>:where(section):not([root]){--JAMA-foreground:#333;--JAMA-current-line:#e5e5e5;--JAMA-background:#ffffff;
  /* --JAMA-background: #f8f8f2; */--JAMA-comment:#6272a4;--JAMA-cyan:#192b2f;--JAMA-blue:#2d696a;--JAMA-green:#6c9a77;--JAMA-orange:#841e2f;--JAMA-pink:#9a2f6b;--JAMA-purple:#4f2d7d;--JAMA-red:#d71635;--JAMA-yellow:#8c9434}div#\:\$p>svg>foreignObject>section .hljs{display:block;overflow-x:auto;padding:0.5em;background:#282a36}div#\:\$p>svg>foreignObject>section .hljs-built_in,div#\:\$p>svg>foreignObject>section .hljs-link,div#\:\$p>svg>foreignObject>section .hljs-section,div#\:\$p>svg>foreignObject>section .hljs-selector-tag{color:#8be9fd}div#\:\$p>svg>foreignObject>section .hljs-keyword{color:#ff79c6}div#\:\$p>svg>foreignObject>section .hljs,div#\:\$p>svg>foreignObject>section .hljs-subst{color:#f8f8f2}div#\:\$p>svg>foreignObject>section .hljs-attr,div#\:\$p>svg>foreignObject>section .hljs-meta-keyword,div#\:\$p>svg>foreignObject>section .hljs-title{color:#50fa7b}div#\:\$p>svg>foreignObject>section .hljs-addition,div#\:\$p>svg>foreignObject>section .hljs-bullet,div#\:\$p>svg>foreignObject>section .hljs-meta,div#\:\$p>svg>foreignObject>section .hljs-name,div#\:\$p>svg>foreignObject>section .hljs-string,div#\:\$p>svg>foreignObject>section .hljs-symbol,div#\:\$p>svg>foreignObject>section .hljs-template-tag,div#\:\$p>svg>foreignObject>section .hljs-template-variable,div#\:\$p>svg>foreignObject>section .hljs-type,div#\:\$p>svg>foreignObject>section .hljs-variable{color:#f1fa8c}div#\:\$p>svg>foreignObject>section .hljs-comment,div#\:\$p>svg>foreignObject>section .hljs-deletion,div#\:\$p>svg>foreignObject>section .hljs-quote{color:#6272a4}div#\:\$p>svg>foreignObject>section .hljs-doctag,div#\:\$p>svg>foreignObject>section .hljs-keyword,div#\:\$p>svg>foreignObject>section .hljs-literal,div#\:\$p>svg>foreignObject>section .hljs-name,div#\:\$p>svg>foreignObject>section .hljs-section,div#\:\$p>svg>foreignObject>section .hljs-selector-tag,div#\:\$p>svg>foreignObject>section .hljs-strong,div#\:\$p>svg>foreignObject>section .hljs-title,div#\:\$p>svg>foreignObject>section .hljs-type{font-weight:bold}div#\:\$p>svg>foreignObject>section .hljs-literal,div#\:\$p>svg>foreignObject>section .hljs-number{color:#bd93f9}div#\:\$p>svg>foreignObject>section .hljs-emphasis{font-style:italic}div#\:\$p>svg>foreignObject>section svg[data-marp-fitting=svg]{max-height:580px}div#\:\$p>svg>foreignObject>section :is(h1,marp-h1),div#\:\$p>svg>foreignObject>section :is(h2,marp-h2),div#\:\$p>svg>foreignObject>section :is(h3,marp-h3),div#\:\$p>svg>foreignObject>section :is(h4,marp-h4),div#\:\$p>svg>foreignObject>section :is(h5,marp-h5),div#\:\$p>svg>foreignObject>section :is(h6,marp-h6){margin:0.2em 0 0 0;max-width:1000px;animation-name:fadeIn;animation-duration:1s;animation-fill-mode:both}div#\:\$p>svg>foreignObject>section :is(h1,marp-h1) strong,div#\:\$p>svg>foreignObject>section :is(h2,marp-h2) strong,div#\:\$p>svg>foreignObject>section :is(h3,marp-h3) strong,div#\:\$p>svg>foreignObject>section :is(h4,marp-h4) strong,div#\:\$p>svg>foreignObject>section :is(h5,marp-h5) strong,div#\:\$p>svg>foreignObject>section :is(h6,marp-h6) strong{font-weight:inherit}div#\:\$p>svg>foreignObject>section li strong{animation-name:fadeIn;animation-duration:1s;animation-fill-mode:both;animation-delay:0.5s}div#\:\$p>svg>foreignObject>section strong{
  /* font-weight: bold; */font-weight:800;
  /* background-color: var(--JAMA-blue); */
  /* color: var(--JAMA-blue); */
  /* text-decoration: underline; */
  /* text-decoration-color: #6c9a77; */
  /* text-decoration-style: solid; */padding:0px 5px 0px 5px;background:-webkit-linear-gradient(right,#6c9a77,#2d696a);-webkit-background-clip:text;-webkit-text-fill-color:transparent}div#\:\$p>svg>foreignObject>section :is(h1,marp-h1){font-size:3.0em;font-weight:800;
  /* margin-top: 100px; */margin-bottom:100px;color:var(--JAMA-foreground)}div#\:\$p>svg>foreignObject>section :is(h2,marp-h2){font-size:1.5em;color:var(--JAMA-blue)}div#\:\$p>svg>foreignObject>section :is(h3,marp-h3){font-size:1.2em;color:var(--JAMA-foreground)}div#\:\$p>svg>foreignObject>section :is(h4,marp-h4){font-size:1.0em;opacity:0.5;font-style:italic;color:var(--JAMA-foreground)}div#\:\$p>svg>foreignObject>section :is(h5,marp-h5){font-size:1em;color:var(--JAMA-blue)}div#\:\$p>svg>foreignObject>section :is(h6,marp-h6){font-size:0.9em;color:var(--JAMA-blue)}div#\:\$p>svg>foreignObject>section p{font-size:0.9em;margin:1em 0 1em 0
  /* transition: 0.3s; */}div#\:\$p>svg>foreignObject>section blockquote{font-size:0.6em;margin:1em 0 0 0;animation-name:fadeIn;animation-duration:1s;animation-fill-mode:both;animation-delay:1.5s}div#\:\$p>svg>foreignObject>section ol>li,div#\:\$p>svg>foreignObject>section ul>li{margin:0.5em 0 0 0;color:var(--JAMA-cyan)}div#\:\$p>svg>foreignObject>section ol>li>p,div#\:\$p>svg>foreignObject>section ul>li>p{margin:0.6em 0 0 0}div#\:\$p>svg>foreignObject>section code{display:inline-block;font-family:"Open Sans",sans-serif;
  /* font-family: "Inter", sans-serif; */
  /* font-family: 'JetBrains Mono', monospace; */font-weight:800;font-size:0.9em;letter-spacing:0.4;margin:0.3em;padding:0.2em 0.4em 0.2em 0.4em;vertical-align:baseline}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre){display:block;min-height:1.0em;color:#fff;overflow:visible}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) code{box-sizing:border-box;line-height:1.0em;background:#333;margin:0;min-width:100%;padding:1.0em;font-size:1em}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) code svg[data-marp-fitting=svg]{max-height:calc(480px - 1em)}div#\:\$p>svg>foreignObject>section blockquote{padding-top:5px;border-top:0.1px solid #555;margin-top:10px;font-size:50%;color:var(--JAMA-foreground);background:var(--JAMA-background);position:absolute;bottom:10px;right:80px;left:80px}div#\:\$p>svg>foreignObject>section blockquote:before{content:"";display:block;font-family:"Times New Roman",serif;font-weight:bold;position:absolute;color:var(--JAMA-green);top:0;left:0}div#\:\$p>svg>foreignObject>section blockquote>:first-child{margin-top:0}div#\:\$p>svg>foreignObject>section blockquote>blockquote>blockquote{font-size:50%;font-weight:400;padding:0;margin:0;border:0;border-top:0.1em dashed #555;position:absolute;bottom:-10px;left:10px}div#\:\$p>svg>foreignObject>section mark{background:transparent}div#\:\$p>svg>foreignObject>section table{border-spacing:0;border-collapse:collapse;border-collapse:collapse;border-radius:10px; /* sets the border radius */overflow:hidden; /* hides the overflow from the rounded corners */margin:1em 0 0 0;transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section table td,div#\:\$p>svg>foreignObject>section table th{padding:0.2em 0.4em;border-width:1px;border-style:solid}div#\:\$p>svg>foreignObject>section table th{background-color:blue; /* sets the background color of the table header */color:white /* sets the text color of the table header to white */}div#\:\$p>svg>foreignObject>section{font-size:28px;font-weight:500;font-family:"Open Sans",sans-serif;line-height:1.15;
  /* letter-spacing: 0.4px; */padding:50px 35px;color:var(--JAMA-foreground);background-color:var(--JAMA-background);border-left:15px solid;border-image:linear-gradient(to bottom,#6c9a77,#2d696a);border-image-slice:1}div#\:\$p>svg>foreignObject>section{--marpit-root-font-size:28px}div#\:\$p>svg>foreignObject>section>:first-child,div#\:\$p>svg>foreignObject>section>header:first-child+*{margin-top:0}div#\:\$p>svg>foreignObject>section a,div#\:\$p>svg>foreignObject>section mark{color:var(--JAMA-red)}div#\:\$p>svg>foreignObject>section code{
  /* background: var(--JAMA-blue); */border-radius:0.7em;border:2px solid var(--JAMA-blue);color:var(--JAMA-blue);animation-name:fadeIn;animation-duration:1s;animation-fill-mode:both;animation-delay:0.4s}div#\:\$p>svg>foreignObject>section :is(h1,marp-h1) strong,div#\:\$p>svg>foreignObject>section :is(h2,marp-h2) strong,div#\:\$p>svg>foreignObject>section :is(h3,marp-h3) strong,div#\:\$p>svg>foreignObject>section :is(h4,marp-h4) strong,div#\:\$p>svg>foreignObject>section :is(h5,marp-h5) strong,div#\:\$p>svg>foreignObject>section :is(h6,marp-h6) strong{background:-webkit-linear-gradient(right,#6c9a77,#2d696a);-webkit-background-clip:text;-webkit-text-fill-color:transparent}div#\:\$p>svg>foreignObject>section :is(h4,marp-h4),div#\:\$p>svg>foreignObject>section header{opacity:0;transform:translateY(-40px);animation:fade-in 1s cubic-bezier(0.4,0,0.2,1) forwards}
/* section pre > code { */
/*   background: #ff4; */
/* } */div#\:\$p>svg>foreignObject>section blockquote:after,div#\:\$p>svg>foreignObject>section blockquote:before,div#\:\$p>svg>foreignObject>section footer,div#\:\$p>svg>foreignObject>section header,div#\:\$p>svg>foreignObject>section section:after{color:var(--JAMA-comment)}div#\:\$p>svg>foreignObject>section table td,div#\:\$p>svg>foreignObject>section table th{border-color:var(--JAMA-current-line);font-size:0.8em}div#\:\$p>svg>foreignObject>section table thead th{background:var(--JAMA-foreground);color:var(--JAMA-background);font-size:0.8em}div#\:\$p>svg>foreignObject>section table tbody>tr:nth-child(2n) td,div#\:\$p>svg>foreignObject>section table tbody>tr:nth-child(2n) th{background:var(--JAMA-current-line);font-size:0.8em}div#\:\$p>svg>foreignObject>section footer,div#\:\$p>svg>foreignObject>section header,div#\:\$p>svg>foreignObject>section:after{box-sizing:border-box;font-size:66%;line-height:30px;
  /* overflow: hidden; */padding:35px 35px;position:absolute;color:var(--JAMA-blue)}div#\:\$p>svg>foreignObject>section:after{--marpit-root-font-size:66%}div#\:\$p>svg>foreignObject>section:after{animation-name:slideInRight;animation-duration:1s;animation-fill-mode:both;animation-timing-function:cubic-bezier(0.6,0.05,0.4,0.95)}div#\:\$p>svg>foreignObject>section header{
  /* background-color: #2d696a; */background:linear-gradient(to left,#2d696a,#6c9a77);color:#ffffff;border-bottom-left-radius:15px;
  /* border-bottom-right-radius: 15px; */
  /* border-left: #2d696a 35px solid; */height:43px;padding-top:5px;right:0;top:0;font-weight:700;text-align:right;max-width:500px}div#\:\$p>svg>foreignObject>section .today{}div#\:\$p>svg>foreignObject>section footer{left:0;right:0;bottom:0}div#\:\$p>svg>foreignObject>section:after{right:0;bottom:0;font-size:80%}div#\:\$p>svg>foreignObject>section:after{--marpit-root-font-size:80%}div#\:\$p>svg>foreignObject>section .free{display:flex;width:100%;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p>svg>foreignObject>section .free div{flex-grow:1}div#\:\$p>svg>foreignObject>section .free>div img{width:auto;transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section .container{display:flex}div#\:\$p>svg>foreignObject>section .half{display:flex;justify-content:center;align-items:left;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p>svg>foreignObject>section .half>div{flex:1;width:calc(50% - calc(var(--marpit-root-font-size, 1rem) * 0.5)); /* set width to 50% minus half the gap */padding-right:0.5em;transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section .free>div img:hover,div#\:\$p>svg>foreignObject>section .half>div:hover{transform:translateY(-10px);transform-origin:center;border-top-width:0px}div#\:\$p>svg>foreignObject>section .columns{display:flex;justify-content:center;align-items:left;gap:calc(var(--marpit-root-font-size, 1rem) * 1)}div#\:\$p>svg>foreignObject>section .columns img,div#\:\$p>svg>foreignObject>section .half img{display:block;margin:0 auto;max-width:100%;height:auto}div#\:\$p>svg>foreignObject>section .columns>div{flex:1;width:calc(50% - calc(var(--marpit-root-font-size, 1rem) * 0.5)); /* set width to 50% minus half the gap */transition:transform 0.3s ease;padding-right:0.5em}div#\:\$p>svg>foreignObject>section .columns div:not(:last-child){border-right:1px dashed green}div#\:\$p>svg>foreignObject>section .columns div:hover{transform:translateY(-30px);transform-origin:center;border-top-width:0px}div#\:\$p>svg>foreignObject>section hr{border:1px solid var(--JAMA-blue)}div#\:\$p>svg>foreignObject>section .dash{border:none;border-top:1px dashed #2d696a;height:0;margin:0.4em 0}div#\:\$p>svg>foreignObject>section a{color:var(--JAMA-cyan)}div#\:\$p>svg>foreignObject>section ul li:hover::marker{transform:scale(1.5);color:#ffb703}div#\:\$p>svg>foreignObject>section li{transition:opacity 1s ease;transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section li::marker{color:#2d696a}div#\:\$p>svg>foreignObject>section li:hover{transform:translateX(-20px);transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section li[data-bespoke-marp-fragment=active]{opacity:1;transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section li[data-bespoke-marp-fragment=inactive]{transition:transform 0.3s ease;visibility:visible;opacity:0.2}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) ol li>:is(span,marp-span){transition:transform 0.5s ease}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) ol li>:is(span,marp-span):hover{font-weight:800;transition:transform 0.3s ease;transform:translateX(40px);
  /* color: var(--JAMA-green); */color:#ffb703}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) ol li:hover:before{color:#ffb703}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) ol li :is(span,marp-span)[data-marp-line-number]:hover{transform:scale(1.2)}div#\:\$p>svg>foreignObject>section td:hover{
  /* box-shadow: 12px 2px 15px rgba(0, 0, 0, 0.3); */color:#2d696a;border:2px solid #2d696a;background-color:white; /* sets the background color of the table header */transition:opacity 0.5s ease}div#\:\$p>svg>foreignObject>section tr:hover{transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section table:hover{
  /* box-shadow: 12px 2px 15px rgba(0, 0, 0, 0.3); */transform:scale(1.01);transition:transform 0.2s ease;box-shadow:0 8px 17px 2px rgba(0,0,0,0.14),0 3px 14px 2px rgba(0,0,0,0.12),0 5px 5px -3px rgba(0,0,0,0.2)}div#\:\$p>svg>foreignObject>section blockquote p:hover{transition:transform 0.3s ease;font-size:2em;padding:0.4em 0.8em 0.4em 0.8em}div#\:\$p>svg>foreignObject>section button{display:inline-block;outline:none;cursor:pointer;font-size:inherit;line-height:1;border-radius:200px;transition-property:background-color,border-color,color,box-shadow,filter;transition-duration:.3s;border:1px solid transparent;letter-spacing:2px;min-width:160px;text-transform:uppercase;white-space:normal;font-weight:700;text-align:center;padding:2px 2px;margin-left:20px;color:#fff;background-color:#2d696a;height:48px;div#\:\$p>svg>foreignObject>section :hover{transform:scale(1.04);background-color:#2d696a}}div#\:\$p>svg>foreignObject>section .container{border:1px solid black;margin:10px}div#\:\$p>svg>foreignObject>section summary{color:#2d696a;font-weight:bold}
/* line num in codebox  */div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) ol{all:unset;display:grid;grid-template-columns:auto 1fr;counter-reset:line-number 0}div#\:\$p>svg>foreignObject>section code ol{padding-right:2.5em}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) ol li{display:contents;color:#fff;font-weight:500;
  /* font-family: "Inter", sans-serif; */font-family:'Overpass Mono',monospace}div#\:\$p>svg>foreignObject>section :is(pre,marp-pre) ol li :is(span,marp-span)[data-marp-line-number]:before{display:block;content:counter(line-number);counter-increment:line-number;text-align:right;color:#595959;font-weight:800;background-color:#222;border-right:5px solid #595959;margin-right:0.51em;padding-right:0.51em;padding-left:0.51em}div#\:\$p>svg>foreignObject>section img[alt*=emojik]{animation:move 2.5s infinite cubic-bezier(0.6,0.05,0.4,0.95)}div#\:\$p>svg>foreignObject>section img[alt*=RLQ]{position:absolute; /* sets the position of the element to absolute */right:80px;bottom:80px}div#\:\$p>svg>foreignObject>section img[alt*=RUQ]{position:absolute; /* sets the position of the element to absolute */right:80px;top:80px}@keyframes fade-in{0%{opacity:0;transform:translateY(-20px)}to{opacity:1;transform:translateY(0)}}@keyframes move{0%{transform:translateX(0)}50%{transform:translateX(-20px)}to{transform:translateX(0)}}@keyframes slideInRight{0%{transform:translateX(100%)}to{transform:translateX(0)}}@keyframes fadeIn{0%{opacity:0}to{opacity:1}}@keyframes fade{0%{opacity:0}50%{opacity:1}to{opacity:0}}div#\:\$p>svg>foreignObject>section svg.markmap{width:200%}div#\:\$p>svg>foreignObject>section img{animation-name:fadeIn;animation-duration:1s;animation-fill-mode:both;animation-delay:0.5s}div#\:\$p>svg>foreignObject>section div[class^=admonition]{margin-left:80px;max-width:80%;animation-name:fadeIn;animation-duration:1s;animation-fill-mode:both;animation-delay:0.5s;transition:transform 0.3s ease}div#\:\$p>svg>foreignObject>section div[class^=admonition]>p>strong{font-weight:bold}
/* div[class^="admonition"] > p  { */
/* } */div#\:\$p>svg>foreignObject>section div[class^=admonition]:hover{
  /* box-shadow: 12px 2px 15px rgba(0, 0, 0, 0.3); */
  /* material style shadow */transform:translateX(20px);transition:transform 0.3s ease;box-shadow:0 8px 17px 2px rgba(0,0,0,0.14),0 3px 14px 2px rgba(0,0,0,0.12),0 5px 5px -3px rgba(0,0,0,0.2)}div#\:\$p>svg>foreignObject>section p.admonition-title:before{padding-left:20px;padding-top:4px;animation:fade 2s cubic-bezier(0.4,0,0.2,1) infinite}div#\:\$p>svg>foreignObject>section .task-list-item-checkbox{transform:scale(1.5)}div#\:\$p>svg>foreignObject>section :is(span,marp-span)[class^=material-symbols-outlined]{position:absolute; /* sets the position of the element to absolute */left:40px;bottom:30px}

/* @theme r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta */div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background]{columns:initial!important;display:block!important;padding:0!important}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background]:after,div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background]:before,div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=content]:after,div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=content]:before{display:none!important}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background]>div[data-marpit-advanced-background-container]{all:initial;display:flex;flex-direction:row;height:100%;overflow:hidden;width:100%}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background]>div[data-marpit-advanced-background-container][data-marpit-advanced-background-direction=vertical]{flex-direction:column}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background][data-marpit-advanced-background-split]>div[data-marpit-advanced-background-container]{width:var(--marpit-advanced-background-split,50%)}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background][data-marpit-advanced-background-split=right]>div[data-marpit-advanced-background-container]{margin-left:calc(100% - var(--marpit-advanced-background-split, 50%))}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=background]>div[data-marpit-advanced-background-container]>figure{all:initial;background-position:center;background-repeat:no-repeat;background-size:cover;flex:auto;margin:0}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=content],div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=pseudo]{background:transparent!important}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background=pseudo],div#\:\$p>svg[data-marpit-svg]>foreignObject[data-marpit-advanced-background=pseudo]{pointer-events:none!important}div#\:\$p>svg>foreignObject>section[data-marpit-advanced-background-split]{width:100%;height:100%}</style></head><body><div class="bespoke-progress-parent"><div class="bespoke-progress-bar"></div></div><div class="bespoke-marp-osc"><button data-bespoke-marp-osc="prev" tabindex="-1" title="Previous slide">Previous slide</button><span data-bespoke-marp-osc="page"></span><button data-bespoke-marp-osc="next" tabindex="-1" title="Next slide">Next slide</button><button data-bespoke-marp-osc="fullscreen" tabindex="-1" title="Toggle fullscreen (f)">Toggle fullscreen</button><button data-bespoke-marp-osc="presenter" tabindex="-1" title="Open presenter view (p)">Open presenter view</button></div><div id=":$p"><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="1" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" style="--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;"><script src="https://cdn.jsdelivr.net/npm/markmap-autoloader@0.15.2"></script>

<h4 id="kfsyscc-hematology-journal-reading">KFSYSCC Hematology Journal Reading</h4>
<h1 is="marp-h1" data-auto-scaling id="how-i-treatbrrefractory-brcrs-and-icansbrafter-car-t-cell-therapy">How I treat<br /><strong>refractory <br />CRS and ICANS</strong><br />after CAR T-cell therapy</h1>
<h2 id="%E6%9E%97%E5%8D%94%E9%9C%86-fellow-1">林協霆, Fellow 1</h2>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="2" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="2" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<h2 id="what-are-we-going-to-discuss-today">What are we going to discuss today?</h2>
<div class="half"><div>
<ul>
<li>Diagnostic criteria for
<ul>
<li><strong>cytokine release syndrome</strong> (CRS)</li>
<li><strong>immune effector cell–associated neurotoxicity syndrome</strong> (ICANS)</li>
</ul>
</li>
<li><strong>Tocilizumab</strong> and <strong>corticosteroids</strong> are commonly used to treat CRS and ICANS.</li>
<li><strong>Preemptive</strong> interventions improve safety of CAR T-cell Tx.</li>
</ul>
</div><div>
<ul>
<li><strong>Anakinra</strong> is emerging as option.</li>
<li>Risk factors for severe toxicities</li>
<li>Mitigation strategies and supportive care measures can improve outcomes in patients with refractory toxicities.</li>
</ul>
</div></div>
</div></div>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="3" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Introduction" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="3" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Introduction;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Introduction</header>

<h2 id="introduction">Introduction</h2>
<ul>
<li>CAR T-cell therapy is potent, but toxicity mitigation is necessary</li>
<li>definition and grading systems for CRS and <strong>immune effector cell–associated neurotoxicity syndrome</strong> (ICANS) have been developed.</li>
<li>Severe toxicities, including refractoriness to standard management with tocilizumab and steroids, still occur.</li>
</ul>
<div class="admonition warning">
<p class="admonition-title">Warning</p>
<p><em>Despite the current stard of treatment, why there's still severe toxicities happend?</em></p>
</div>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="4" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Introduction" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="4" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Introduction;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Introduction</header>
<h2 id="tocilizumab-and-corticosteroids-for-crs-and-icans">Tocilizumab and Corticosteroids for CRS and ICANS</h2>
<ul>
<li>Tocilizumab and corticosteroids were initially used for severe CRS and/or ICANS.</li>
<li>Now, these therapies are increasingly used at <strong>earlier stages</strong> to reduce the incidence of severe toxicity.
<ul>
<li><strong>Pre-emptive</strong> tocilizumab and/or steroids with lower grade toxicity can prevent more severe manifestations.</li>
<li><strong>Prophylactic treatment</strong> before any toxicity is observed is also being explored.</li>
</ul>
</li>
<li>Refractory CRS and/or ICANS are defined as <strong>persistent or progressive disease despite optimal use of tocilizumab and/or steroids.</strong></li>
<li>Available strategies have shifted towards <strong>prevention</strong> of ≥grade <strong>3</strong> CRS and ICANS.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="5" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Introduction" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="5" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Introduction;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Introduction</header>
<h2 id="astct-consensus-grading-for-crs">ASTCT Consensus Grading for CRS</h2>
<table>
<thead>
<tr>
<th>Clinical Parameter</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>≥38 C</td>
<td>≥38 C</td>
<td>≥38 C</td>
<td>≥38 C</td>
</tr>
<tr>
<td>Hypotension</td>
<td>None</td>
<td>No vasopressors</td>
<td>Vasopressor ± vasopressin</td>
<td>Requires multiple vasopressors <br />(not vasopressin)</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>None</td>
<td>Low-flow nasal cannula or blow-by</td>
<td>High-flow nasal cannula, face mask, <br />non-rebreather, Venturi mask</td>
<td>CPAP, BiPAP, mechanical ventilation</td>
</tr>
</tbody>
</table>
<div class="admonition attention">
<p class="admonition-title">Attention</p>
<p>In grades 2 to 4, inclusion is fever plus hypotension and/or hypoxia.</p>
</div>
<blockquote>
<p>Lee D, Santomasso B, Locke F, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625-638.</p>
</blockquote>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="6" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Introduction" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="6" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Introduction;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Introduction</header>
<h2 id="grading-for-icans-part-i">Grading for ICANS: part I</h2>
<p><img src="https://i.imgur.com/yWs8FM3.png" alt="Figure:" style="height:550px;" /></p>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="7" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Introduction" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="7" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Introduction;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Introduction</header>
<h2 id="grading-for-icans-part-ii">Grading for ICANS: part II</h2>
<p><img src="https://i.imgur.com/TURFUWh.png" alt="Figure:" style="width:1150px;" /></p>
<p><img src="https://i.imgur.com/4Ez7otw.png" alt="Figure:" style="width:1150px;" /></p>
<blockquote>
<p>Lee, Daniel W., et al. &quot;ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.&quot; Biology of blood and marrow transplantation 25.4 (2019): 625-638.</p>
</blockquote>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="8" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Introduction" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="8" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Introduction;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Introduction</header>
<h2 id="workup-or-evaluation-and-supportive-care-recommendations-all-grades">Workup or evaluation and supportive care recommendations (all grades)</h2>
<ul>
<li>CBC, CMP, Mg, Phos, CRP, LDH, uric acid, fibrinogen, PT/PTT, and ferritin</li>
<li>blood and urine cultures, CXR</li>
<li>If <strong>neutropenic</strong>, follow institutional neutropenic fever guidelines</li>
<li>If grade 2 or higher CRS (eg, shock or hypoxia)
<ul>
<li>should be monitored with continuous cardiac telemetry and pulse oximetry.</li>
</ul>
</li>
<li>severe CRS, consider performing an echocardiogram to assess cardiac function.</li>
<li>Perform cardiac monitoring in patients who experience at least G2 CRS, clinically significant arrhythmia, and additionally as clinically indicated</li>
<li>Consider screening for <strong>CMV</strong> and <strong>EBV</strong></li>
<li>Consider chest or abdominal CT imaging, brain MRI, and/or lumbar puncture.</li>
</ul>
<blockquote>
<p>Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol. 2021;39(35):3978-3992. doi:10.1200/JCO.21.01992</p>
</blockquote>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="9" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Introduction" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="9" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Introduction;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Introduction</header>
<h1 id="cases">Cases</h1>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="10" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 1" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="10" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 1;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 1</header>

<h2 id="case-1-refractory-crs-in-a-dlbcl-patient">Case 1: Refractory CRS in a DLBCL Patient</h2>
<ul>
<li>A 59-year-old male</li>
<li><code>DLBCL</code> received CD19 CAR T-cell therapy after 3 prior lines of therapy.</li>
<li>On day 0, he developed grade 1 CRS and progressed to grade 2 CRS with hypoxia by day 3.</li>
<li><code>Tocilizumab at 8 mg/kg</code> was administered, but he required a second dose and <code>dexamethasone, 10 mg IV every 6 hours</code>, because of persistent fevers and worsening hypoxia.</li>
<li>By day 4, <strong>ferritin x3 within 24 hours to 23,000 ng/mL</strong>, → ICU for high-flow oxygen and vasopressors.</li>
<li>DIC, thrombocytopenia, and AKI creatinine ≥3 mg/dL.</li>
<li>The corticosteroid dose was increased to <code>methylprednisolone 1 g IV daily</code>.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="11" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 1" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="11" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 1;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 1</header>
<div class="half"><div>
<ul>
<li>Patients with <strong>high tumor burden and primary refractory disease</strong> are
<ul>
<li>at high risk of both CRS and lymphoma relapse.</li>
</ul>
</li>
<li>CD19 CAR T-cell products incorporating 4-1BB (ie, tisagenlecleucel)  have lower toxicity rates than those costimulated by CD28 (axi-cel), but severe CRS has been reported for all products.</li>
</ul>
<div class="admonition info">
<p class="admonition-title">Info</p>
<p>tisa-cel lower toxicity than axi-cel</p>
</div>
</div><div>
<p><img src="https://i.imgur.com/yvF6ilP.png" alt="" style="height:250px;" /></p>
<p><img src="https://i.imgur.com/Jo8zGwZ.png" alt="" style="height:250px;" /></p>
</div></div>
</div></div>
<blockquote>
<p>Dean EA, Mhaskar RS, Lu H, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances. 2020;4(14):3268-3276. doi:10.1182/bloodadvances.2020001900</p>
</blockquote>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="12" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 1" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="12" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 1;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 1</header>
<ul>
<li>With persistent grade 2 CRS despite repeat doses of tocilizumab and/or single dose corticosteroids, or progression to grade 3 CRS,
<ul>
<li>dexamethasone is often escalated up to <strong>10 mg IV every 6 hours</strong>.</li>
<li><strong>methylprednisolone 1 g IV per day</strong> and/or initiation of alternative CRS-directed therapies.</li>
</ul>
</li>
<li>Once a patient has received 2 doses of tocilizumab
<ul>
<li>repeat doses are generally not recommended.</li>
</ul>
</li>
<li>Consideration of both alternative etiologies and incorporation of additional therapies is imperative for refractory CRS.</li>
</ul>
<div class="admonition warning">
<p class="admonition-title">Warning</p>
<p>Tocilizumab maximum two dose</p>
</div>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="13" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 1" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="13" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 1;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 1</header>
<h2 id="case-1-management-of-refractory-crs-in-a-dlbcl-patient">Case 1: Management of Refractory CRS in a DLBCL Patient</h2>
<ul>
<li>Concurrent infections, including bacteremia and CMV viremia, were identified in the patient with refractory CRS.
<ul>
<li>Antibiotics and CMV treatment were initiated.</li>
</ul>
</li>
<li>Early restaging via abdominal CT scan showed
<ul>
<li>stabilization of the abdominal mass.</li>
</ul>
</li>
<li><strong>Anakinra 100 mg IV every 6 hours</strong> was started on the afternoon of day 4 for refractory CRS.</li>
<li>The patient's condition subsequently improved, and anakinra and corticosteroid doses were tapered over 1 week.</li>
<li>He experienced a maximum ICANS of grade 1.</li>
<li>His day 30 positron emission tomography/CT scan showed a complete metabolic remission</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="14" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 1" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="14" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 1;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 1</header>
<h2 id="car-hematotox">CAR-HEMATOTOX</h2>
<h3 id="a-model-for-car-t-cell%E2%80%93related-hematologic-toxicity-in-relapsedrefractory-large-b-cell-lymphoma">a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma</h3>
<p><img src="https://i.imgur.com/qOzleBL.png" alt="Figure:" style="width:1150px;" /></p>
<blockquote>
<p>Rejeski, K., Perez, A., Iacoboni, G., Penack, O., Bücklein, V., Jentzsch, L., ... &amp; Subklewe, M. (2022). The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. Journal for ImmunoTherapy of Cancer, 10(5).</p>
</blockquote>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="15" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 1" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="15" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 1;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 1</header>
<h2 id="anakinra">Anakinra</h2>
<ul>
<li>Disease-modifying Antirheumatic Drugs</li>
<li>Recombinant human <code>interleukin-1 (IL-1)</code> receptor antagonist</li>
<li>Administer <strong>sub-Q, 100mg</strong></li>
<li>Uses: Rheumatoid Arthritis, Cryopyrin-associated Periodic Syndromes, Deficiency of Interleukin-1 Receptor Antagonist</li>
<li>Warnings:
<ul>
<li>Opportunistic infections (fungal, mycobacterial, bacterial)</li>
<li>Concomitant use of TNF blocking agents (e.g., adalimumab, etanercept, infliximab) not recommended.</li>
<li>Neutropenia</li>
</ul>
</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="16" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 1" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="16" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 1;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 1</header>
<h2 id="differential-diagnosis-for-early-clinical-deterioration-after-car-t-cell-therapy">Differential Diagnosis for Early Clinical Deterioration after CAR T-cell Therapy</h2>
<ul>
<li>Top differential diagnoses include:
<ul>
<li><strong>refractory CRS</strong>, <strong>infection</strong>, and <strong>cancer progression</strong>.</li>
</ul>
</li>
<li>Infectious workup includes standard cultures performed at first fever and every 24 to 48 hours while the patient is persistently febrile.
<ul>
<li><strong>CMV/adenoviremia</strong> and other viremias,</li>
<li>nasopharyngeal viral testing for respiratory infections</li>
</ul>
</li>
<li>The patient had no evidence of gastrointestinal perforation or ischemia, which can occur among patients with abdominal lymphoma.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="17" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 1" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="17" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 1;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 1</header>
<h2 id="management-of-refractory-crs">Management of Refractory CRS</h2>
<ul>
<li>For CRS refractory to high doses of corticosteroids:
<ul>
<li><strong>anakinra</strong> often considered.</li>
</ul>
</li>
<li>Once a clinical response is achieved, anakinra and corticosteroids:
<ul>
<li>tapered as indicated, prolonged use at high doses is not indicated.</li>
</ul>
</li>
<li>Extra vigilance and enhanced antimicrobial prophylaxis is warranted,</li>
<li><strong>Cytopenias</strong> are a complication of, and can further complicate, refractory CRS</li>
</ul>
<div class="admonition warning">
<p class="admonition-title">Warning</p>
<p>prolonged use at high doses is not indicated</p>
</div>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="18" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 1" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="18" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 1;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 1</header>
<h2 id="high-risk-of-developing-severe-crsicans-including-patients-with">High risk of developing severe CRS/ICANS, including patients with</h2>
<ul>
<li>older patients</li>
<li>medically frail</li>
<li>bulky disease</li>
<li>high tumor burden</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="19" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 2" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="19" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 2;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 2</header>

<h2 id="case-2-cd19-car-t-cell-therapy-for-refractory-follicular-lymphoma-transformed-to-dlbcl">Case 2: CD19 CAR T-cell Therapy for Refractory Follicular Lymphoma Transformed to DLBCL</h2>
<ul>
<li>A 71-year-old woman</li>
<li><strong>follicular lymphoma</strong> transformed to DLBCL was referred for receipt of CD19 CAR T cells for treatment of progressive nodal and extranodal disease refractory to 3 prior lines of therapy.</li>
<li>She was not given any bridging therapy before axicabtagene ciloleucel.</li>
<li>On day 2, she developed grade 1 CRS, with persistent fever until day 5, when she was given dexamethasone 10 mg IV once.</li>
<li>On day 6, she presented with grade 2 CRS and grade 1 ICANS characterized by fever, hypoxia, and dysphasia.</li>
<li>She received <strong>tocilizumab 8 mg/kg</strong> and <strong>dexamethasone 10 mg IV</strong> once for the ICANS.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="20" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 2" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="20" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 2;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 2</header>
<h2 id="early-intervention-and-corticosteroid-use-in-car-t-cell-therapy">Early Intervention and Corticosteroid Use in CAR T-cell Therapy</h2>
<ul>
<li>The comparison of cohorts 1 and 2 with cohort 4 found that the median overall corticosteroid exposure declined from 6886 mg to 939 mg with earlier use of corticosteroids.</li>
<li>Overall, the trend in clinical practice is toward intervening earlier at lower grades of CRS and ICANS.</li>
<li>Age alone is not a driving factor for toxicity severity, as shown by findings from studies such as Ram et al's comparison of geriatric and younger patients.</li>
</ul>
<div class="admonition info">
<p class="admonition-title">Info</p>
<p><strong>Earlier intervention</strong> with corticosteroids may help to limit a more prolonged course of corticosteroids.</p>
</div>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="21" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 2" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="21" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 2;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 2</header>
<h3 id="protocol-specified-ae-management-in-cohorts-1--2-and-cohort-4-of-zuma-1">Protocol-specified AE management in cohorts 1 + 2 and cohort 4 of ZUMA-1</h3>
<h4 id="a-comparison-of-ae-management-in-cohorts-1--2-and-cohort-4-of-zuma-1-yes-or-no-indicates-whether-tocilizumab-or-corticosteroid-was-or-was-not-administered-respectively">(A) Comparison of AE management in cohorts 1 + 2 and cohort 4 of ZUMA-1. ‘Yes’ or ‘No’ indicates whether tocilizumab or corticosteroid was or was not administered, respectively</h4>
<p><img src="https://i.imgur.com/isYtII7.png" alt="Figure:" style="width:1150px;" /></p>
<blockquote>
<p>Topp, Max S., et al. &quot;Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma.&quot; British Journal of Haematology 195.3 (2021): 388-398.</p>
</blockquote>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="22" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 2" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="22" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 2;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 2</header>
<div class="free"><div>
<p><img src="https://i.imgur.com/TmsjUwj.png" alt="Figure:" style="height:550px;" /></p>
</div><div>
<p>(B) Tocilizumab and corticosteroid guidelines for AE management in cohort 4 of ZUMA-1.</p>
</div></div>
</div></div>
<blockquote>
<p>Topp, Max S., et al. &quot;Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma.&quot; British Journal of Haematology 195.3 (2021): 388-398.</p>
</blockquote>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="23" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 2" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="23" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 2;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 2</header>
<h2 id="early-intervention-for-patients-at-high-risk-of-toxicity">Early Intervention for Patients at High Risk of Toxicity</h2>
<ul>
<li>In patients who may not tolerate prolonged low-grade CRS (such as elderly patients or those who are frail) or patients who are at high risk of subsequent progression to severe toxicities, early intervention with tocilizumab and/or corticosteroids during lower grade toxicities is recommended.</li>
<li>Although results of studies incorporating prophylactic corticosteroids are promising, additional studies are needed before systematically incorporating the prophylactic use of steroids for risk mitigation.</li>
</ul>
<div class="admonition info">
<p class="admonition-title">Info</p>
<p>elderly patients or those who are frail <img class="emoji" draggable="false" alt="👉" src="https://cdn.jsdelivr.net/gh/jdecked/twemoji@14.1.2/assets/svg/1f449.svg" data-marp-twemoji=""/> ppx corticosteroids</p>
</div>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="24" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 2" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="24" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 2;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 2</header>
<h4 id="back-to-case-3">Back to Case 3</h4>
<h2 id="management-of-grade-3-icans-in-a-patient-receiving-car-t-cell-therapy">Management of Grade 3 ICANS in a Patient Receiving CAR T-cell Therapy</h2>
<ul>
<li>On day 8, the patient showed <strong>global aphasia</strong> and <strong>epileptiform activity</strong> upon an EEG, consistent with <strong>grade 3 ICANS</strong>,
<ul>
<li>despite concurrent improvement in CRS to grade 1</li>
</ul>
</li>
<li>For treatment of ICANS, she received <strong>methylprednisolone 1 gm IV daily for 2 days</strong> followed by a dexamethasone taper to discontinuation over 2 weeks.</li>
<li>She also received <strong>anakinra 100 mg IV</strong> every 6 hours, which was tapered over a 10-day course.</li>
<li>Seizure prophylaxis with levetiracetam (500 mg daily) was increased to therapeutic doses and 2 additional antiepileptics, lacosamide and phenytoin, were initiated to control seizure activity based on neurology consultation.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="25" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 2" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="25" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 2;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 2</header>
<h3 id="neurotoxicity-ntx-and-association-with-crs-after-conditioning-chemotherapy-and-19%E2%80%9328z-car-t-cell-infusion">Neurotoxicity (NTX) and association with CRS after conditioning chemotherapy and 19–28z CAR T cell infusion</h3>
<div class="half"><div>
<p><img src="https://i.imgur.com/fHn202f.png" alt="Figure:" style="height:450px;" /></p>
</div><div>
<p><img src="https://i.imgur.com/IBRDddD.png" alt="Figure:" style="height:450px;" /></p>
</div></div>
</div></div>
<blockquote>
<p>Santomasso, Bianca D., et al. &quot;Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia.&quot; Cancer discovery 8.8 (2018): 958-971.</p>
</blockquote>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="26" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 2" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="26" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 2;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 2</header>
<ul>
<li>The patient was treated in the ICU for several days for more frequent monitoring of her neurological status.</li>
<li>Upon resolution of CRS and ICANS, she was noted to have CMV viremia, cytopenias, and severe deconditioning, which substantially prolonged her inpatient stay.</li>
<li>Her day 30 positron emission tomography/CT scan showed a complete metabolic remission, and she was ultimately discharged from the hospital on day 65 after CAR T-cell infusion.</li>
</ul>
<p><img src="https://emojik.vercel.app/s/%F0%9F%8C%B7_%F0%9F%8E%8A?size=256" alt="emojik RLQ" style="height:100px;" /></p>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="27" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 2" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="27" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 2;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 2</header>
<h2 id="use-of-corticosteroids-in-management-of-crs-and-icans">Use of Corticosteroids in Management of CRS and ICANS</h2>
<ul>
<li>Corticosteroids are generally accepted for refractory CRS and as first-line therapy for ICANS.</li>
<li>Dexamethasone is frequently recommended for ICANS because it crosses the <strong>blood-brain barrier</strong>.</li>
<li>Package inserts for US FDA-approved CD19 CAR T-cell products recommend dexamethasone or methylprednisolone for the treatment of severe ICANS.</li>
<li>There are <em>conflicting data</em> on the impact that corticosteroid exposure has on CAR T-cell efficacy, with some studies noting no change in the efficacy, whereas others show decreased efficacy.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="28" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 2" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="28" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 2;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 2</header>
<ul>
<li>The use of <strong>intrathecal corticosteroids</strong> has also been reported for use in severe or refractory ICANS, yet its use as a systemic steroid-sparing therapy warrants prospective study.</li>
<li>TODO: find out what is the intrathecal corticosteroid ????</li>
<li>The use of intrathecal therapy may be limited by concurrent thrombocytopenia and coagulopathy observed in patients with concurrent CRS.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="29" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 3" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="29" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 3;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 3</header>

<h2 id="case-3-use-of-cd19-car-t-cell-therapy-in-down-syndrome-and-rb-all">Case 3: Use of CD19 CAR T-cell Therapy in  Down Syndrome and rB-ALL</h2>
<ul>
<li>A 15-year-old male with constitutional trisomy 21 and
<ul>
<li>relapsed B-cell acute lymphoblastic leukemia (B-ALL)</li>
<li>presented with 30% bone marrow blasts with low-level circulating peripheral blasts.</li>
</ul>
</li>
<li>The patient received LD chemotherapy and CAR T-cell infusion for relapsed B-ALL with 30% marrow involvement after bridging chemotherapy.</li>
<li>He was on physiologic hydrocortisone for adrenal insufficiency.</li>
<li>He developed fever, representing grade 1 CRS, on day 5 and was initially responsive to supportive measures.</li>
<li>However, he developed more persistent fevers, hypotension, rising creatinine, and decreasing urine output (grade 2 CRS) over 3 days.</li>
<li>He was given tocilizumab 8 mg/kg for persistent grade 2 CRS to prevent grade 3 CRS.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="30" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 3" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="30" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 3;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 3</header>
<h2 id="management-of-adrenal-insufficiency-and-crs-mitigation-in-cd19-car-t-cell-therapy">Management of Adrenal Insufficiency and CRS Mitigation in CD19 CAR T-cell Therapy</h2>
<ul>
<li>For patients with established or suspected adrenal insufficiency, maintenance of physiologic dosing with escalation to stress-dosing during CRS should be considered to maintain hemodynamic stability and offset the need for higher doses of corticosteroids.</li>
<li>Consistent with preemptive strategies tested by Gardner et al, tocilizumab was given for persistent symptoms of mild CRS and before the development of life-threatening toxicities (eg, grade 3 CRS).</li>
<li>The approach of preventing more severe CRS/ICANS in children and young adults may be a unique consideration of younger patients in which baseline comorbidities may be less severe, and patients may be able to better tolerate grade 2 CRS/ICANS without more severe complications.</li>
<li>In patients with DS: monitor congenital cardiac complications.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="31" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 3" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="31" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 3;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 3</header>
<h2 id="development-and-management-of-hlh-like-complications-after-cd19-car-t-cell-therapy">Development and Management of HLH-Like Complications after CD19 CAR T-cell Therapy</h2>
<ul>
<li>Approximately 10 days after tocilizumab, the patient developed a rapidly rising <strong>ferritin level</strong> (&gt;100 000 μg/L) and hepatic transaminitis (&gt;10 × upper limit of normal [ULN]), disproportional to C-reactive protein, which was decreasing.</li>
<li>The patient also developed severe <strong>hypofibrinogenemia</strong> (&lt;100 mg/dL)</li>
<li>Despite stable vital signs, laboratory parameters worsened, prompting the initiation of methylprednisolone (2 mg/kg per day) and anakinra (8 mg/kg per day) to treat <strong>HLH-like complications</strong>.</li>
<li>After a short course of steroids and 1 week of anakinra with tapering doses, laboratory values normalized.</li>
<li>The patient achieved a minimal residual disease-negative complete response.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="32" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 3" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="32" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 3;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 3</header>
<h2 id="hlh-like-toxicities-as-a-potential-complication-of-car-t-cell-therapy">HLH-Like Toxicities as a Potential Complication of CAR T-cell Therapy</h2>
<ul>
<li>Recently termed as <strong>immune effector cell-associated HLH-like syndrome</strong> (IEC-HS) through an American Society for Transplantation and Cellular Therapy (ASTCT) effort, this hyperinflammatory syndrome manifests with cytopenia, hepatic dysfunction, hypofibrinogenemia, and hyperferritinemia.</li>
<li>Because both primary/familial and secondary forms of HLH are pathologically linked to T-cell activation and immune dysregulation, this complication can be particularly challenging to diagnose with underlying hematologic malignancies.</li>
<li>Initially described as part of severe CRS, more recent reports have described delayed manifestations of HLH-like toxicities even with low-grade CRS, particularly in patients receiving <strong>CD22</strong> CAR T cells.</li>
<li>In BCMA-targeting CAR T-cell therapies, in which severe CRS is less frequent, HLH-or macrophage activation syndrome-like toxicities are also becoming more apparent and are listed as potential toxicities on the FDA-approved package inserts.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="33" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Case 3" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="33" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Case 3;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Case 3</header>
<h2 id="management-of-hlh-like-toxicities-in-cd19-car-t-cell-therapy">Management of HLH-Like Toxicities in CD19 CAR T-cell Therapy</h2>
<ul>
<li>In case 3, <strong>anakinra and corticosteroids</strong> were used as first-line strategies based on their established role in the treatment of primary or secondary HLH.</li>
<li>This approach has been recently endorsed by the ASTCT Committee on Cellular Therapy, although further study is needed.</li>
<li>Tocilizumab was not indicated in case 3, as the patient's clinical presentation and stable vital signs did not meet the standard criteria for CRS.</li>
<li>Multicenter efforts are ongoing to establish clear criteria to improve understanding of IEC-HS and formulate optimal treatment approaches, particularly for refractory cases.</li>
<li>Therapeutic strategies for refractory IEC-HS are under study and include ruxolitinib, emapalumab, and etoposide.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="34" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Prevention for r/r CRS/ICANS" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="34" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Prevention for r/r CRS/ICANS;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Prevention for r/r CRS/ICANS</header>

<p><br /><br /><br /></p>
<h1 id="prevention-of-severe-andor-refractory-crsicans">Prevention of severe and/or refractory CRS/ICANS</h1>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="35" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Prevention for r/r CRS/ICANS" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="35" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Prevention for r/r CRS/ICANS;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Prevention for r/r CRS/ICANS</header>
<h2 id="key-points">Key Points</h2>
<ul>
<li>Distinguishing toxicities that respond to first-line approaches from those requiring additional investigations or interventions is a critical consideration.</li>
<li>Early identification and preemptive interventions in high risk pt</li>
<li>Risk-mitigation preventive strategies for those at high risk of toxicity may improve outcomes.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="36" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Prevention for r/r CRS/ICANS" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="36" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Prevention for r/r CRS/ICANS;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Prevention for r/r CRS/ICANS</header>
<h4 id="approach-to-mitigate-severe-crsicans-and-progressive-toxicities-despite-the-optimal-use-of-first-line-therapies">Approach to mitigate severe CRS/ICANS and progressive toxicities despite the optimal use of first-line therapies</h4>
<p><img src="https://i.imgur.com/uBnwbc5.png" alt="Figure:" style="height:550px;" /></p>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="37" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Prevention for r/r CRS/ICANS" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="37" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Prevention for r/r CRS/ICANS;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Prevention for r/r CRS/ICANS</header>
<h3 id="disease-type-and-biology">Disease type and biology</h3>
<ul>
<li>Highly proliferative aggressive diseases, are at higher risk of severe CRS/ICANS than diseases,
<ul>
<li>DLBCL and B-ALL, follicular lymphoma, or myeloma.</li>
</ul>
</li>
<li><strong>marginal zone lymphoma</strong> has a higher rate of CRS/ICANS than follicular lymphoma, and transformed marginal zone lymphoma may be at higher risk than transformed follicular lymphoma or de novo DLBCL.</li>
<li>severe and refractory CRS and ICANS may occur in any disease type,
<ul>
<li>especially among heavily pretreated and refractory patients.</li>
</ul>
</li>
<li>Management recommendations for cases of severe and refractory CRS or ICANS are generalizable across disease types.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="38" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Prevention for r/r CRS/ICANS" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="38" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Prevention for r/r CRS/ICANS;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Prevention for r/r CRS/ICANS</header>
<h3 id="disease-burden">Disease burden</h3>
<ul>
<li>higher inflammatory cytokine levels and CAR T-cell expansion.
<ul>
<li>increased risk of relapse after CAR T-cell therapy, even though remission rates are often comparable.</li>
</ul>
</li>
<li>severe CRS are at a higher risk for CAR T-cell failure.</li>
<li>Debunking patients before CAR T-cell therapy can be tried, but patients receive CAR T-cell therapy because they are resistant to other treatments.</li>
<li>Debulking radiation, however, the optimal timing, dose, and field for bridging radiation therapy are unknown.</li>
</ul>
<div class="admonition warning">
<p class="admonition-title">Warning</p>
<p>rapidly progressive disease, high tumor burdens, or poor performance status may be better candidates for therapies other than CAR T cells.</p>
</div>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="39" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Prevention for r/r CRS/ICANS" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="39" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Prevention for r/r CRS/ICANS;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Prevention for r/r CRS/ICANS</header>
<h3 id="car-t-cell-construct">CAR T-cell construct</h3>
<ul>
<li><strong>CD28-costimulated</strong> CAR T-cell products demonstrate higher rates of CRS and ICANS compared to 4-1BB-costimulated products in DLBCL with CD19 CAR T cells.</li>
<li>ICANS may be more severe when <strong>targeting CD19</strong>, potentially because of the on-target, off-tumor targeting of CD19 on <strong>brain mural cells</strong>.</li>
<li>Unique movement-related toxicities have been observed when targeting BCMA, possibly because of off-tumor expression of these targets in and around the brain.</li>
<li>Even when the target and costimulatory domain are identical, kinetics of toxicity may differ between products, affecting clinical management.</li>
</ul>
<div class="admonition info">
<p class="admonition-title">Info</p>
<p>When multiple CAR T-cell products are available for a given disease, consideration of a product with potentially lower toxicity</p>
</div>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="40" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Pharmacologic interventions" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="40" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Pharmacologic interventions;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Pharmacologic interventions</header>

<h2 id="pharmacologic-interventions-for-severe-andor-refractory-toxicities">Pharmacologic interventions for severe and/or refractory toxicities</h2>
<ul>
<li>Evidence-based data on the use of pharmacologic interventions for treatment of severe and/or refractory toxicities in CD19 CAR T-cell therapy are generally lacking.</li>
<li>Limited data is available from single-institutional experiences or case reports, preclinical data, T-cell–directed mechanisms of action, or adopted for use based on efficacy in alternative hyperinflammatory settings.</li>
<li>Risk of infection with additive use of immunosuppressive agents is a concern.</li>
<li>Consultation with infectious disease specialists is suggested to optimize infection surveillance strategies and use of prophylactic/preemptive antimicrobials.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="41" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Pharmacologic interventions" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="41" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Pharmacologic interventions;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Pharmacologic interventions</header>

<h2 id="anti-cytokine-directed">Anti-Cytokine Directed</h2>
<h3 id="anakinra-1">Anakinra</h3>
<ul>
<li><strong>IL-1</strong> receptor antagonist.
<ul>
<li>reduce signs/symptoms and slow the progression of damage in
<ul>
<li>adults with moderately to severely active RA who have failed ≥1 DMARDs, or</li>
<li>neonatal-onset multisystem inflammatory disorder.</li>
</ul>
</li>
<li>Administered by IV or SC, with preference for IV administration in patients with edema in whom SC administration may not be as reliable.</li>
</ul>
</li>
</ul>
<h3 id="siltuximab">Siltuximab</h3>
<ul>
<li><strong>IL-6</strong> antagonist.
<ul>
<li>for <strong>multicentric Castleman disease</strong> who are HIV- and HHV-8–negative.</li>
<li>limited to <strong>2L</strong> or rCRS/ICANS after the use of multiple other agents.</li>
</ul>
</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="42" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Pharmacologic interventions" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="42" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Pharmacologic interventions;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Pharmacologic interventions</header>
<h3 id="emapalumab">Emapalumab</h3>
<ul>
<li><strong>IFN-γ–blocking</strong> antibody.</li>
<li>Used for the treatment of adult and pediatric patients with primary HLH with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.</li>
<li>Clinical experience is limited.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="43" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Pharmacologic interventions" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="43" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Pharmacologic interventions;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Pharmacologic interventions</header>
<h2 id="t-cell-targeted">T-Cell Targeted</h2>
<h3 id="antithymocyte-globulin-atg">Antithymocyte globulin (ATG)</h3>
<ul>
<li>Direct T-cell targeting.</li>
<li>Used for prophylaxis and treatment of acute rejection in patients receiving a kidney transplant, or use in conjunction with concomitant immunosuppression.</li>
<li>Potential use is based on clinical efficacy of targeting T cells.</li>
<li>Data on CRS/ICANS are limited.</li>
<li>Risk of infection/immunosuppression is high.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="44" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Pharmacologic interventions" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="44" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Pharmacologic interventions;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Pharmacologic interventions</header>
<h3 id="alemtuzumab-anti-cd52">Alemtuzumab (anti-CD52)</h3>
<ul>
<li>Depletion of T and B cells by binding to CD52 on the cell surface.</li>
<li>Used for treatment of patients with relapsing forms of MS.</li>
<li>Emerging use to facilitate engraftment of allogeneic or off-the-shelf CAR T cells.</li>
</ul>
<h3 id="cyclophosphamide">Cyclophosphamide</h3>
<ul>
<li>Alkylating agent targeting T cells.</li>
<li>Multiple indications for use in pediatrics and adults with malignancies and minimal change nephrotic syndrome.</li>
<li>Could be used for eradicating T cells.</li>
<li>Limited experience (single case report) in the use for refractory CRS/ICANS.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="45" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Pharmacologic interventions" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="45" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Pharmacologic interventions;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Pharmacologic interventions</header>
<h2 id="tkis">TKIs</h2>
<h3 id="dasatinib-tki-bcr-abl">Dasatinib: TKI (BCR-ABL)</h3>
<ul>
<li>Used for adults in chronic, accelerated, or blast phase of Ph+ CML; for adults with Ph+ ALL.</li>
<li>Preclinical studies demonstrate the ability of dasatinib to suppress CAR T-cell cytotoxicity, cytokine secretion, and proliferation.</li>
</ul>
<h3 id="ibrutinib">Ibrutinib</h3>
<ul>
<li>BTK inhibitor.</li>
<li>Used for adults with MCL who have received at least 1 prior therapy, for CLL with 17p deletion, or in those who have received at least 1 prior therapy or who have Waldenstrom macroglobulinemia.</li>
<li>Emerging clinical data incorporating ibrutinib suggest the potential of reducing CRS severity.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="46" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Pharmacologic interventions" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="46" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Pharmacologic interventions;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Pharmacologic interventions</header>
<h3 id="ruxolitinib-or-alternative-jak1-inhibitors">Ruxolitinib or alternative JAK1 inhibitors</h3>
<ul>
<li><strong>JAK inhibitor</strong>.</li>
<li>Used for the treatment of adults with myelofibrosis and polycythemia vera, and for the treatment of adults and pediatric patients aged &gt;12 y with steroid refractory acute GVHD or chronic GVHD after failure of &gt;1-2 lines of systemic therapy.</li>
<li>Preclinical studies demonstrate a role of JAK pathway singling blockade and dose-dependent reduction of multiple cytokines implicated in CRS.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="47" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Pharmacologic interventions" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="47" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Pharmacologic interventions;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Pharmacologic interventions</header>
<h2 id="car-t-cell-construct-based-safety-switches-in-cd19-car-t-cell-therapy">CAR T-Cell Construct-Based Safety Switches in CD19 CAR T-cell Therapy</h2>
<p>TODO: 看不太懂這是什麼</p>
<ul>
<li>CAR T-cell constructs can incorporate suicide switches or alternative transcriptional controls</li>
<li>Suicide switches can be targeted by the synthetic dimerizing drug rimiducid</li>
<li>Truncated-targetable receptors, such as EGFR or CD20, can be targeted by monoclonal antibodies like cetuximab or rituximab</li>
<li>These agents can be used to eradicate CAR T cells in cases of refractory disease or life-threatening CAR T-cell–mediated toxicities.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="48" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Pharmacologic interventions" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="48" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Pharmacologic interventions;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Pharmacologic interventions</header>
<h3 id="anti-car-t-cell-directed-strategies">Anti-CAR T-cell-directed strategies</h3>
<ul>
<li>When patients have severe or refractory CRS and/or ICANS, targeting the remaining CAR T cells is often the last resort.</li>
<li>Anti-CAR T-cell–directed interventions may include chemotherapy, T-cell–directed therapies, tyrosine kinase inhibitors, or CAR construct–directed therapies.</li>
<li>Experience with these interventions is limited, and infection risk may be particularly high, especially when given after multiple prior immunosuppressive approaches.</li>
<li>Further studies are needed to evaluate the efficacy and safety of these interventions for the treatment of severe or refractory CRS/ICANS.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="49" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Supportive Care" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="49" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Supportive Care;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Supportive Care</header>

<h2 id="supportive-care-measures-for-management-of-severe-or-refractory-toxicities-in-cd19-car-t-cell-therapy">Supportive Care Measures for Management of Severe or Refractory Toxicities in CD19 CAR T-cell Therapy</h2>
<ul>
<li>management of:
<ul>
<li>cytopenias</li>
<li>infections</li>
<li>hypotension</li>
<li>coagulopathy</li>
<li>electrolyte disturbances</li>
</ul>
</li>
<li>Early intervention and management of adverse effects may improve patient outcomes and reduce the risk of long-term complications.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="50" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Supportive Care" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="50" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Supportive Care;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Supportive Care</header>
<h2 id="supportive-care-measures-for-patients-with-severe-or-refractory-crs-or-icans-in-cd19-car-t-cell-therapy">Supportive Care Measures for Patients with Severe or Refractory CRS or ICANS in CD19 CAR T-cell Therapy</h2>
<h3 id="neurology">Neurology</h3>
<ul>
<li>Identify patients at high risk of developing ICANS and engage neurology early.</li>
<li>Tailor duration of steroids in patients with severe ICANS to treat toxicity but limit adverse side effects.</li>
</ul>
<h3 id="immunehematologic">Immune/Hematologic</h3>
<ul>
<li>Limit the duration of high-dose steroids for the management of toxicity to diminish immune suppression.</li>
<li>Use cytokine-directed treatments, such as anakinra, as a steroid-sparing approach.</li>
<li>Optimize approaches to treat ongoing cytopenias.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="51" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Supportive Care" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="51" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Supportive Care;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Supportive Care</header>
<h3 id="infectious-disease">Infectious Disease</h3>
<ul>
<li><strong>trimethoprim-sulfamethoxazole</strong>, for Pneumocystis jirovecii prophylaxis.</li>
<li>Ppx acyclovir or valacyclovir, for herpes virus prophylaxis before conditioning chemotherapy.</li>
<li>broad-spectrum antibiotics and blood cultures for patients with neutropenic fever.</li>
<li>Assess for CMV, adeno- or other viremias in patients with persistent cytopenia after treatment.</li>
<li>antifungal prophylaxis in patients with prolonged immunosuppression due to CRS/ICANS management and cytopenias.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="52" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Supportive Care" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="52" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Supportive Care;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Supportive Care</header>
<h3 id="rehabilitation">Rehabilitation</h3>
<ul>
<li>Involve inpatient rehabilitation services for patients, particularly those with lengthy hospital stays or those who received prolonged steroids, after they are clinically stable.</li>
<li>Encourage engagement of caregivers and social workers.</li>
</ul>
<h3 id="cognitivepsychosocial">Cognitive/Psychosocial</h3>
<ul>
<li>Consult psychiatry or psychiatric oncology to aid in the management of delirium, particularly in older or pediatric patients who develop ICANS.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="53" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Supportive Care" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="53" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Supportive Care;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Supportive Care</header>
<h3 id="medical">Medical</h3>
<ul>
<li>Patients with severe or refractory CRS and/or ICANS typically receive prolonged courses of high-dose corticosteroids with other immunosuppressive agents.</li>
<li>To mitigate the deleterious effects of corticosteroids, the use of steroid-sparing, cytokine-directed medications for prophylaxis, or treatment of CAR-mediated toxicity should be assessed.</li>
<li>Infectious complications are frequent after CAR T-cell therapy, and severe CRS and prolonged corticosteroid exposure are risk factors for severe infections.</li>
<li>Prophylactic antimicrobials are essential to reduce infections, including emergence of latent and opportunistic infections.</li>
<li>Exposure to broad-spectrum antibiotics targeting obligate anaerobes within the 4 weeks before CAR T-cell therapy has been associated with worse outcomes, possibly because of alterations in the intestinal microbiome.</li>
<li>The impact of antibiotics administered after CAR T-cell therapy is not yet known.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="54" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Supportive Care" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="54" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Supportive Care;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Supportive Care</header>
<h3 id="rehabilitation-and-cognitive-and-psychosocial-considerations">Rehabilitation and cognitive and psychosocial considerations</h3>
<ul>
<li>Multiple factors, including CRS and ICANS, immobility, malnutrition, infection, and the catabolic effects of prolonged corticosteroids, may lead to a deterioration in the conditioning and mental status</li>
<li>Early considerations for rehabilitation to address deconditioning and steroid myopathy that may result in proximal limb weakness is needed</li>
<li>Emerging research suggests the presence of short- and long-term biobehavioral effects of CAR T-cell therapy, but more work is needed in this area to understand the long-term implications for patients who experience severe or refractory CAR-mediated toxicities.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="55" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Conclusions" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="55" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Conclusions;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Conclusions</header>

<h2 id="conclusions">Conclusions</h2>
<p><img src="https://i.imgur.com/cgvReVa.png" alt="Figure:" style="height:550px;" /></p>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="56" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Conclusions" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="56" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Conclusions;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Conclusions</header>
<h2 id="take-home-messages">Take Home Messages</h2>
<ul>
<li>Prophylaxis and early treatment of CRS appear to play a role in preventing subsequent severe toxicity in CD19 CAR T-cell therapy.</li>
<li>Rates of severe CRS and ICANS may depend on histology, tumor burden, and CAR T-cell product type, making interpretation of single-arm trials challenging.</li>
<li>Caution is needed because limited data is available on the effect of these interventions on antitumor efficacy, and patients at lower risk typically do not need these interventions.</li>
</ul>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="57" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Conclusions" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="57" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Conclusions;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Conclusions</header>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
</foreignObject></svg><svg data-marpit-svg="" viewBox="0 0 1280 720"><foreignObject width="1280" height="720"><section id="58" data-paginate="true" data-footer="&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
" data-header="Conclusions" data-theme="r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta" data-marpit-pagination="58" data-marpit-pagination-total="58" style="--paginate:true;--footer:&lt;link rel=&quot;stylesheet&quot; href=&quot;https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200&quot; /&gt;
&lt;span class=&quot;material-symbols-outlined&quot;&gt;
navigate_next
&lt;/span&gt;
;--header:Conclusions;--theme:r8kl0sgn1aj70ihz9eyloswrh7srz0cjemu6cb8ta;">
<header>Conclusions</header>
<h1 id="thank-you-for-your-time-and-attention">Thank you for your time and attention</h1>
<h1 id="have-a-nice-day"><em>Have a nice day</em></h1>
<p><img src="https://emojik.vercel.app/s/%E2%98%80%EF%B8%8F_%F0%9F%98%8E?size=256" alt="emojik RLQ" style="height:300px;" /></p>
<footer><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20..48,100..700,0..1,-50..200" /><br />
<span class="material-symbols-outlined"><br />
navigate_next<br />
</span><br />
</footer>
</section>
<script>!function(){"use strict";const t={h1:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"1"},style:"display: block; font-size: 2em; margin-block-start: 0.67em; margin-block-end: 0.67em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h2:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"2"},style:"display: block; font-size: 1.5em; margin-block-start: 0.83em; margin-block-end: 0.83em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h3:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"3"},style:"display: block; font-size: 1.17em; margin-block-start: 1em; margin-block-end: 1em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h4:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"4"},style:"display: block; margin-block-start: 1.33em; margin-block-end: 1.33em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h5:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"5"},style:"display: block; font-size: 0.83em; margin-block-start: 1.67em; margin-block-end: 1.67em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},h6:{proto:()=>HTMLHeadingElement,attrs:{role:"heading","aria-level":"6"},style:"display: block; font-size: 0.67em; margin-block-start: 2.33em; margin-block-end: 2.33em; margin-inline-start: 0px; margin-inline-end: 0px; font-weight: bold;"},span:{proto:()=>HTMLSpanElement},pre:{proto:()=>HTMLElement,style:"display: block; font-family: monospace; white-space: pre; margin: 1em 0; --marp-auto-scaling-white-space: pre;"}},e="data-marp-auto-scaling-wrapper",i="data-marp-auto-scaling-svg",n="data-marp-auto-scaling-container";class s extends HTMLElement{constructor(){super(),this.svgPreserveAspectRatio="xMinYMid meet";const t=t=>([e])=>{const{width:i,height:n}=e.contentRect;this[t]={width:i,height:n},this.updateSVGRect()};this.attachShadow({mode:"open"}),this.containerObserver=new ResizeObserver(t("containerSize")),this.wrapperObserver=new ResizeObserver(((...e)=>{t("wrapperSize")(...e),this.flushSvgDisplay()}))}static get observedAttributes(){return["data-downscale-only"]}connectedCallback(){var t,s,o,r,a;this.shadowRoot.innerHTML=`\n<style>\n  svg[${i}] { display: block; width: 100%; height: auto; vertical-align: top; }\n  span[${n}] { display: table; white-space: var(--marp-auto-scaling-white-space, nowrap); width: max-content; }\n</style>\n<div ${e}>\n  <svg part="svg" ${i}>\n    <foreignObject><span ${n}><slot></slot></span></foreignObject>\n  </svg>\n</div>\n    `.split(/\n\s*/).join(""),this.wrapper=null!==(t=this.shadowRoot.querySelector(`div[${e}]`))&&void 0!==t?t:void 0;const l=this.svg;this.svg=null!==(o=null===(s=this.wrapper)||void 0===s?void 0:s.querySelector(`svg[${i}]`))&&void 0!==o?o:void 0,this.svg!==l&&(this.svgComputedStyle=this.svg?window.getComputedStyle(this.svg):void 0),this.container=null!==(a=null===(r=this.svg)||void 0===r?void 0:r.querySelector(`span[${n}]`))&&void 0!==a?a:void 0,this.observe()}disconnectedCallback(){this.svg=void 0,this.svgComputedStyle=void 0,this.wrapper=void 0,this.container=void 0,this.observe()}attributeChangedCallback(){this.observe()}flushSvgDisplay(){const{svg:t}=this;t&&(t.style.display="inline",requestAnimationFrame((()=>{t.style.display=""})))}observe(){this.containerObserver.disconnect(),this.wrapperObserver.disconnect(),this.wrapper&&this.wrapperObserver.observe(this.wrapper),this.container&&this.containerObserver.observe(this.container),this.svgComputedStyle&&this.observeSVGStyle(this.svgComputedStyle)}observeSVGStyle(t){const e=()=>{const i=(()=>{const e=t.getPropertyValue("--preserve-aspect-ratio");if(e)return e.trim();return`x${(({textAlign:t,direction:e})=>{if(t.endsWith("left"))return"Min";if(t.endsWith("right"))return"Max";if("start"===t||"end"===t){let i="rtl"===e;return"end"===t&&(i=!i),i?"Max":"Min"}return"Mid"})(t)}YMid meet`})();i!==this.svgPreserveAspectRatio&&(this.svgPreserveAspectRatio=i,this.updateSVGRect()),t===this.svgComputedStyle&&requestAnimationFrame(e)};e()}updateSVGRect(){var t,e,i,n,s,o,r;let a=Math.ceil(null!==(e=null===(t=this.containerSize)||void 0===t?void 0:t.width)&&void 0!==e?e:0);const l=Math.ceil(null!==(n=null===(i=this.containerSize)||void 0===i?void 0:i.height)&&void 0!==n?n:0);void 0!==this.dataset.downscaleOnly&&(a=Math.max(a,null!==(o=null===(s=this.wrapperSize)||void 0===s?void 0:s.width)&&void 0!==o?o:0));const c=null===(r=this.svg)||void 0===r?void 0:r.querySelector(":scope > foreignObject");if(null==c||c.setAttribute("width",`${a}`),null==c||c.setAttribute("height",`${l}`),this.svg&&(this.svg.setAttribute("viewBox",`0 0 ${a} ${l}`),this.svg.setAttribute("preserveAspectRatio",this.svgPreserveAspectRatio),this.svg.style.height=a<=0||l<=0?"0":""),this.container){const t=this.svgPreserveAspectRatio.toLowerCase();this.container.style.marginLeft=t.startsWith("xmid")||t.startsWith("xmax")?"auto":"0",this.container.style.marginRight=t.startsWith("xmi")?"auto":"0"}}}const o=(t,{attrs:e={},style:i})=>class extends t{constructor(...t){super(...t);for(const[t,i]of Object.entries(e))this.hasAttribute(t)||this.setAttribute(t,i);this.attachShadow({mode:"open"})}static get observedAttributes(){return["data-auto-scaling"]}connectedCallback(){this._update()}attributeChangedCallback(){this._update()}_update(){const t=i?`<style>:host { ${i} }</style>`:"";let e="<slot></slot>";const{autoScaling:n}=this.dataset;if(void 0!==n){e=`<marp-auto-scaling exportparts="svg:auto-scaling" ${"downscale-only"===n?"data-downscale-only":""}>${e}</marp-auto-scaling>`}this.shadowRoot.innerHTML=t+e}};let r;const a=Symbol();let l;const c="marpitSVGPolyfill:setZoomFactor,",d=Symbol(),g=Symbol();const h=()=>{const t="Apple Computer, Inc."===navigator.vendor,e=t?[u]:[],i={then:e=>(t?(async()=>{if(void 0===l){const t=document.createElement("canvas");t.width=10,t.height=10;const e=t.getContext("2d"),i=new Image(10,10),n=new Promise((t=>{i.addEventListener("load",(()=>t()))}));i.crossOrigin="anonymous",i.src="data:image/svg+xml;charset=utf8,%3Csvg%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%22%20width%3D%2210%22%20height%3D%2210%22%20viewBox%3D%220%200%201%201%22%3E%3CforeignObject%20width%3D%221%22%20height%3D%221%22%20requiredExtensions%3D%22http%3A%2F%2Fwww.w3.org%2F1999%2Fxhtml%22%3E%3Cdiv%20xmlns%3D%22http%3A%2F%2Fwww.w3.org%2F1999%2Fxhtml%22%20style%3D%22width%3A%201px%3B%20height%3A%201px%3B%20background%3A%20red%3B%20position%3A%20relative%22%3E%3C%2Fdiv%3E%3C%2FforeignObject%3E%3C%2Fsvg%3E",await n,e.drawImage(i,0,0),l=e.getImageData(5,5,1,1).data[3]<128}return l})().then((t=>{null==e||e(t?[u]:[])})):null==e||e([]),i)};return Object.assign(e,i)};let p,m;function u(t){const e="object"==typeof t&&t.target||document,i="object"==typeof t?t.zoom:t;window[g]||(Object.defineProperty(window,g,{configurable:!0,value:!0}),document.body.style.zoom=1.0001,document.body.offsetHeight,document.body.style.zoom=1,window.addEventListener("message",(({data:t,origin:e})=>{if(e===window.origin)try{if(t&&"string"==typeof t&&t.startsWith(c)){const[,e]=t.split(","),i=Number.parseFloat(e);Number.isNaN(i)||(m=i)}}catch(t){console.error(t)}})));let n=!1;Array.from(e.querySelectorAll("svg[data-marpit-svg]"),(t=>{var e,s,o,r;t.style.transform||(t.style.transform="translateZ(0)");const a=i||m||t.currentScale||1;p!==a&&(p=a,n=a);const l=t.getBoundingClientRect(),{length:c}=t.children;for(let i=0;i<c;i+=1){const n=t.children[i];if(n.getScreenCTM){const t=n.getScreenCTM();if(t){const i=null!==(s=null===(e=n.x)||void 0===e?void 0:e.baseVal.value)&&void 0!==s?s:0,c=null!==(r=null===(o=n.y)||void 0===o?void 0:o.baseVal.value)&&void 0!==r?r:0,d=n.children.length;for(let e=0;e<d;e+=1){const s=n.children[e];if("SECTION"===s.tagName){const{style:e}=s;e.transformOrigin||(e.transformOrigin=`${-i}px ${-c}px`),e.transform=`scale(${a}) matrix(${t.a}, ${t.b}, ${t.c}, ${t.d}, ${t.e-l.left}, ${t.f-l.top}) translateZ(0.0001px)`;break}}}}}})),!1!==n&&Array.from(e.querySelectorAll("iframe"),(({contentWindow:t})=>{null==t||t.postMessage(`${c}${n}`,"null"===window.origin?"*":window.origin)}))}function v({once:t=!1,target:e=document}={}){const i=function(t=document){if(t[d])return t[d];let e=!0;const i=()=>{e=!1,delete t[d]};Object.defineProperty(t,d,{configurable:!0,value:i});let n=[],s=!1;(async()=>{try{n=await h()}finally{s=!0}})();const o=()=>{for(const e of n)e({target:t});s&&0===n.length||e&&window.requestAnimationFrame(o)};return o(),i}(e);return t?(i(),()=>{}):i}p=1,m=void 0;const b=Symbol(),w=(e=document)=>{if("undefined"==typeof window)throw new Error("Marp Core's browser script is valid only in browser context.");if(((e=document)=>{const i=window[a];i||customElements.define("marp-auto-scaling",s);for(const n of Object.keys(t)){const s=`marp-${n}`,a=t[n].proto();null!=r||(r=!!document.createElement("div",{is:"marp-auto-scaling"}).outerHTML.startsWith("<div is")),r&&a!==HTMLElement?i||customElements.define(s,o(a,{style:t[n].style}),{extends:n}):(i||customElements.define(s,o(HTMLElement,t[n])),e.querySelectorAll(`${n}[is="${s}"]`).forEach((t=>{t.outerHTML=t.outerHTML.replace(new RegExp(`^<${n}`,"i"),`<${s}`).replace(new RegExp(`</${n}>$`,"i"),`</${s}>`)})))}window[a]=!0})(e),e[b])return e[b];const i=v({target:e}),n=()=>{i(),delete e[b]},l=Object.assign(n,{cleanup:n,update:()=>w(e)});return Object.defineProperty(e,b,{configurable:!0,value:l}),l},y=document.currentScript;w(y?y.getRootNode():document)}();
</script></foreignObject></svg></div><div class="bespoke-marp-note" data-index="0" tabindex="0"><p>Add this anywhere in your Markdown file</p></div><div class="bespoke-marp-note" data-index="1" tabindex="0"><p>已經建立起細胞激素釋放症候群 (CRS) 和免疫效應細胞相關神經毒性症候群 (ICANS) 的診斷標準。</p><p>Tocilizumab 和皮質類固醇常被用來治療 CRS 和 ICANS。</p><p>先發制人的干預措施改善了 CAR T 細胞療法的安全性。</p><p>持續性或惡化的 CRS 和 ICANS 難以治療且會損害患者的治療結果。</p><p>抗藥性 CRS 和/或 ICANS 需要不同的治療方法。</p><p>Anakinra 正在成為一種有前景的治療選擇。</p><p>應考慮嚴重毒性的風險因素。</p><p>減輕策略和支持性護理措施可以改善具有抗藥性毒性的患者的治療結果。</p></div><div class="bespoke-marp-note" data-index="2" tabindex="0"><p>![RUQ emojik height:100px](https://emojik.vercel.app/s/🤔_😵?size=256)</p><p>CAR T 細胞療法很有效，但要廣泛使用，必須降低毒性。</p><p>Tocilizumab 在獲得第一個 CAR T 細胞核准時，就核准用來治療細胞激素釋放症候群 (CRS)。</p><p>已經開發出 CRS 和 免疫效應細胞相關神經毒性症候群 (ICANS) 的定義和分級系統。</p><p>關於各種 CD19 靶向 CAR T 細胞建構體的經驗，改進了對毒性特徵的辨別。</p><p>CAR T 細胞療法的第二個十年累積了更多使用新型建構體的經驗，而且在預防和控制發炎性毒性方面做得更好。</p><p>仍然會發生嚴重的毒性，包括對 tocilizumab 和類固醇的標準療法產生抗藥性。</p></div><div class="bespoke-marp-note" data-index="3" tabindex="0"><p>Tocilizumab 和類固醇最初用於治療嚴重的 CRS 和/或 ICANS。</p><p>現在，這些療法越來越常在 早期階段 使用，以降低嚴重毒性的發生率。</p><p>在毒性較低的情況下 先發制人 使用 tocilizumab 和/或類固醇可以防止更嚴重的表現。</p><p>也在探討在觀察到任何毒性之前就進行 預防性治療 的可能性。</p><p>現有策略已轉向預防 ≥3 級的 CRS 和 ICANS。</p></div><div class="bespoke-marp-note" data-index="9" tabindex="0"><p>![emojik height:70px](https://emojik.vercel.app/s/😵_😷?size=256)</p><p>一名 59 歲的男性 DLBCL 患者在接受過 3 次前線療法後接受了 CD19 CAR T 細胞療法。</p><p>在第 0 天，他出現 1 級 CRS 並在第 3 天進展為伴有缺氧的 2 級 CRS。</p><p>給予 8 毫克/公斤的托珠單抗，但由於持續發燒和缺氧惡化，他需要第二劑和地塞米松，每 6 小時 10 毫克靜脈注射。</p><p>到第 4 天，鐵蛋白在 24 小時內增加三倍至 23,000 ng/mL，他需要轉移到 ICU 以接受高流量氧氣和升壓藥。</p><p>他出現瀰漫性血管內凝血、血小板減少和急性腎損傷，血清肌酐 ≥3 mg/dL。</p><p>將皮質類固醇劑量增加至甲基潑尼松龍 1 克靜脈注射，每日一次。</p></div><div class="bespoke-marp-note" data-index="11" tabindex="0"><p>腫瘤負擔高和原發性難治性疾病的患者同時具有較高的 CRS 和淋巴瘤復發風險。</p><p>結合 4-1BB 的 CD19 CAR T 細胞產品的毒性率低於那些由 CD28 共刺激的產品，但所有產品均有報導嚴重的 CRS。</p><p>對於高危患者或需要重複使用托珠單抗治療低級別 CRS 的患者的管理通常包括地塞米松 10 毫克靜脈注射或口服。</p><p>儘管重複劑量的托珠單抗和/或單劑量皮質類固醇，持續存在 2 級 CRS，或進展為 3 級 CRS，地塞米松通常會增加至每 6 小時 10 毫克靜脈注射。</p><p>對於 4 級 CRS，市售結構的包裝說明書推薦甲基潑尼松龍 1 克靜脈注射，每日一次，和/或開始其他 CRS 導向療法。</p><p>患者一旦接受了 2 劑托珠單抗，通常不建議重複給藥。</p><p>考慮其他病因並納入其他療法對於難治性 CRS 至關重要。</p></div><div class="bespoke-marp-note" data-index="12" tabindex="0"><p>在難治性 CRS 患者中發現了併發感染，包括菌血症和巨細胞病毒血症。</p><p>開始使用抗生素和 CMV 治療。</p><p>早期通過腹部 CT 掃描重新分期顯示腹部腫塊穩定。</p><p>在第 4 天下午開始每 6 小時靜脈注射 anakinra 100 毫克，以治療難治性 CRS。</p><p>隨後患者病情好轉，anakinra 和皮質類固醇劑量在 1 周內逐漸減少。</p><p>他出現了 1 級的最大 ICANS。</p><p>他第 30 天的正電子發射斷層掃描/CT 掃描顯示完全代謝緩解</p></div><div class="bespoke-marp-note" data-index="15" tabindex="0"><p>最主要的鑑別診斷包括難治性 CRS、感染和癌症進展。</p><p>感染檢查包括在首次發燒時以及患者持續發燒時每 24 至 48 小時進行的標準培養。</p><p>臨床惡化時進行的檢查包括 CMV/腺病毒血症和其他病毒血症評估、呼吸道感染的鼻咽病毒測試以及成像檢查以檢查隱匿感染或疾病進展。</p><p>在這種情況下，感染或癌症進展都不能解釋臨床表現的嚴重程度。</p><p>患者沒有胃腸道穿孔或缺血的跡象，這在腹部淋巴瘤患者中可能會發生。</p></div><div class="bespoke-marp-note" data-index="16" tabindex="0"><p>對於對高劑量皮質類固醇難治的 CRS，通常會考慮使用白介素-1 受體拮抗劑 anakinra。</p><p>一旦達到臨床反應，可以根據臨床指徵逐漸減少 anakinra 和皮質類固醇的用量，通常不建議長期高劑量使用。</p><p>鑑於接受這些免疫抑制療法並可能因同時存在細胞減少症而進一步受損的患者感染風險增加，因此需要額外的警惕和增強的抗菌預防措施。</p><p>細胞減少症是難治性 CRS 的併發症，並且會進一步使難治性 CRS 複雜化，並在隨附的“我的治療方法”文章中有更詳細的討論。</p></div><div class="bespoke-marp-note" data-index="18" tabindex="0"><p>一名 71 岁的女性，滤泡性淋巴瘤转化为 DLBCL，被转诊接受 CD19 CAR T 细胞治疗，以治疗对 3 种既往治疗方案难治的进行性结节和结外疾病。</p><p>在接受阿西卡塔单抗之前，她没有接受任何桥接治疗。</p><p>第 2 天，她出现 1 级 CRS，持续发烧至第 5 天，然后给予地塞米松 10 毫克静脉注射一次。</p><p>第 6 天，她出现 2 级 CRS 和 1 级 ICANS，表现为发烧、缺氧和构音障碍。</p><p>她接受了托珠单抗 8 毫克/公斤和地塞米松 10 毫克静脉注射一次，用于治疗 ICANS。</p></div><div class="bespoke-marp-note" data-index="19" tabindex="0"><p>倾向评分匹配显示，早期干预与较低的严重毒性率相关；然而，该分析仅限于匹配已知因素，可能无法平衡队列之间的所有差异。</p><p>早期使用皮质类固醇可能有助于限制更长时间的皮质类固醇疗程。</p><p>将队列 1 和 2 与队列 4 进行比较发现，随着皮质类固醇的早期使用，总体皮质类固醇的平均暴露量从 6886 毫克下降到 939 毫克。</p><p>总体而言，临床实践的趋势是在 CRS 和 ICANS 的较低级别进行更早的干预。</p><p>对于老年患者，CAR T 细胞治疗后的疗效数据有限。</p><p>年龄本身并不是毒性严重程度的驱动因素，正如 Ram 等人比较老年患者和年轻患者的研究结果所示。</p></div><div class="bespoke-marp-note" data-index="22" tabindex="0"><p>对于可能无法耐受长期低级别 CRS（例如老年患者或体弱患者）的患者或随后发生严重毒性风险高的患者，建议在低级别毒性期间早期使用托珠单抗和/或皮质类固醇。</p><p>虽然纳入预防性皮质类固醇的研究结果很有希望，但在系统纳入预防性使用类固醇以降低风险之前，还需要进行更多研究。</p></div><div class="bespoke-marp-note" data-index="25" tabindex="0"><p>第 8 天，患者出现进行性失语和脑电图上的癫痫样活动，符合 3 级 ICANS，尽管同时 CRS 改善至 1 级。</p><p>为了治疗 ICANS，她接受了甲泼尼龙 1 克静脉注射，每天 2 次，持续 2 天，然后逐渐减少地塞米松，在 2 周内停药。</p><p>她还接受了每 6 小时静脉注射 100 毫克的阿那白滞素，并在 10 天的疗程中逐渐减少剂量。</p><p>根据神经科会诊，用左乙拉西坦（500 毫克每日一次）进行癫痫发作预防，并增加了 2 种其他抗癫痫药拉科酰胺和苯妥英，以控制癫痫发作活动。</p><p>患者在 ICU 接受了几天的治疗，以便更频繁地监测她的神经状态。</p><p>在 CRS 和 ICANS 消退后，她被发现患有 CMV 病毒血症、细胞减少症和严重失调，这大大延长了她的住院时间。</p><p>她的第 30 天正电子发射断层扫描/CT 扫描显示完全代谢缓解，最终在 CAR T 细胞输注后第 65 天出院。</p></div><div class="bespoke-marp-note" data-index="27" tabindex="0"><p>鑑於支持 IL-1 在 ICANS 的病理生理學中的作用的數據，包括與 ICANS 相關的腦脊液升高，阿那白滯素已 increasingly 用于治療難治性 ICANS。</p><p>阿那白滯素是一種重組 IL-1 受體拮抗劑，已獲得 FDA 批准，可治療類風濕性關節炎。</p><p>一項正在進行的 2 期試驗的初步數據測試預防性阿那白滯素以預防 CRS 和 ICANS 顯示出有希望的結果；然而，迫切需要在兒科患者中对其进行评估。</p><p>據報導，鞘內皮質類固醇也可用於治療嚴重或難治性 ICANS，但其作為全身類固醇替代療法的使用值得前瞻性研究。</p><p>鞘內治療的使用可能會受到血小板減少症和凝血功能障礙的限制，這在患有併發 CRS 的患者中觀察到。</p></div><div class="bespoke-marp-note" data-index="28" tabindex="0"><p>該患者在橋接化療後接受 LD 化療和 CAR T 細胞輸注，治療復發性 B-ALL，骨髓受累 30%。</p><p>他因腎上腺功能不全而接受生理劑量的氫化可的松。</p><p>他在第 5 天出現發燒，代表 1 級 CRS，最初對支持性措施有反應。</p><p>然而，在 3 天內，他出現了更持久的發燒、低血壓、肌酐升高和尿量減少（2 級 CRS）。</p><p>他接受了 8 mg/kg 的托珠單抗治療持續的 2 級 CRS，以防止 3 級 CRS。</p></div><div class="bespoke-marp-note" data-index="29" tabindex="0"><p>對於確診或疑似腎上腺功能不全的患者，應考慮在 CRS 期間維持生理劑量並升至應激劑量，以維持血流動力學穩定並抵消對更高劑量皮質類固醇的需求。</p><p>與 Gardner 等人測試的先發制人的策略一致，托珠單抗被用於治療持續的輕度 CRS 症狀以及在危及生命的中毒症狀（例如 3 級 CRS）出現之前。</p><p>在兒童和成人中預防更嚴重的 CRS/ICANS 的方法可能是年輕患者的一個獨特考慮因素，其中基線合併症可能不太嚴重，並且患者可能能夠在沒有更嚴重併發症的情況下更好地耐受 2 級 CRS/ICANS。</p><p>在患有 DS</p></div><div class="bespoke-marp-note" data-index="30" tabindex="0"><p>在使用托珠单抗大约 10 天后，患者铁蛋白水平迅速升高（&gt;100,000 μg/L），肝转氨酶升高（&gt;10 × 正常值上限 [ULN]），与正在下降的 C 反应蛋白不相称。</p><p>患者还出现了严重的低纤维蛋白原血症（&lt;100 mg/dL），尽管凝血酶原时间和部分凝血活酶时间正常。</p><p>尽管生命体征稳定，但实验室参数恶化，促使开始使用甲泼尼松龙（每天 2 毫克/公斤）和阿那白滞素（每天 8 毫克/公斤）来治疗类噬血综合征样并发症。</p><p>经过短疗程的类固醇和 1 周的阿那白滞素递减剂量治疗后，实验室值恢复正常。</p><p>患者达到微小残留病阴性完全缓解。</p><p>鉴于额外的免疫抑制，他在使用大剂量类固醇和阿那白滞素期间继续进行抗真菌预防。</p></div><div class="bespoke-marp-note" data-index="31" tabindex="0"><p>HLH 样毒性正日益被视为 CAR T 细胞疗法的潜在并发症，并且可能是严重且危及生命的。</p><p>最近通过美国移植和细胞治疗学会 (ASTCT) 的努力将其命名为免疫效应细胞相关的 HLH 样综合征 (IEC-HS)，这种高炎症综合征表现为细胞减少、肝功能障碍、低纤维蛋白原血症和高铁蛋白血症。</p><p>由于原发性/家族性和继发性形式的 HLH 在病理上与 T 细胞活化和免疫失调相关，因此这种并发症在诊断潜在血液系统恶性肿瘤时可能特别具有挑战性。</p><p>最初被描述为严重 CRS 的一部分，最近的报道描述了 HLH 样毒性的延迟表现，即使是低级别 CRS，特别是在接受 CD22 CAR T 细胞的患者中。</p><p>在靶向 BCMA 的 CAR T 细胞疗法中，严重 CRS 的发生率较低，HLH 或巨噬细胞激活综合征样毒性也变得越来越明显，并被列为 FDA 批准的包装插页上的潜在毒性。</p></div><div class="bespoke-marp-note" data-index="32" tabindex="0"><p>在案例 3 中，基于阿那白滞素和皮质类固醇在治疗原发性或继发性噬血细胞综合征 (HLH) 中确立的作用，将其用作一线策略。</p><p>美国血液与骨髓移植学会 (ASTCT) 细胞治疗委员会最近批准了这种方法，尽管需要进一步研究。</p><p>病例 3 中未指明托珠单抗，因为患者的临床表现和稳定的生命体征不符合 CRS 的标准标准。</p><p>多中心正在努力建立明确的标准，以提高对 IEC-HS 的认识，并制定最佳治疗方法，特别是对于难治性病例。</p><p>难治性 IEC-HS 的治疗策略正在研究中，包括芦可替尼、依马替尼和依托泊苷。</p></div><div class="bespoke-marp-note" data-index="36" tabindex="0"><p>- TODO:</p><p>- Tumor biology affects the risk of toxicity, with increased regulatory T cells in the tumor microenvironment linked to decreased risk of ICANS in patients with DLBCL.</p><p>高度增殖的侵袭性疾病，例如 DLBCL 和 B-ALL，比滤泡性淋巴瘤或骨髓瘤等疾病发生严重 CRS/ICANS 的风险更高。</p><p>在惰性淋巴瘤中，边缘区淋巴瘤的 CRS/ICANS 发生率高于滤泡性淋巴瘤，转化边缘区淋巴瘤的风险可能高于转化滤泡性淋巴瘤或 de novo DLBCL。</p><p>然而，任何疾病类型都可能发生严重和难治性 CRS 和 ICANS，特别是在接受过大量预处理和难治性患者中。</p><p>针对严重和难治性 CRS 或 ICANS 病例的管理建议可概括为所有疾病类型。</p><p>肿瘤生物学影响毒性的风险，肿瘤微环境中调节性 T 细胞增加与 DLBCL 患者 ICANS 风险降低相关。</p></div><div class="bespoke-marp-note" data-index="40" tabindex="0"><p>header:Pharmacologic interventions</p></div><div class="bespoke-marp-note" data-index="46" tabindex="0"><p>- Based on the CAR T-cell construct and the incorporation of either suicide switches (eg, inducible Caspase 9 targeted by the synthetic dimerizing drug rimiducid) or alternative transcriptional controls, or truncated-targetable receptors (eg, EGFR or CD20) that can be targeted by monoclonal antibodies (eg, cetuximab or rituximab), these agents can be considered for use when eradicating the CAR T cell in the setting of refractory and when life-threatening CAR T-cell–mediated toxicities are present.</p></div><script>/*!! License: https://unpkg.com/@marp-team/marp-cli@3.2.1/lib/bespoke.js.LICENSE.txt */
!function(){"use strict";function e(e){return e&&e.__esModule&&Object.prototype.hasOwnProperty.call(e,"default")?e.default:e}var t={from:function(e,t){var n,r=1===(e.parent||e).nodeType?e.parent||e:document.querySelector(e.parent||e),o=[].filter.call("string"==typeof e.slides?r.querySelectorAll(e.slides):e.slides||r.children,(function(e){return"SCRIPT"!==e.nodeName})),i={},a=function(e,t){return(t=t||{}).index=o.indexOf(e),t.slide=e,t},s=function(e,t){i[e]=(i[e]||[]).filter((function(e){return e!==t}))},l=function(e,t){return(i[e]||[]).reduce((function(e,n){return e&&!1!==n(t)}),!0)},c=function(e,t){o[e]&&(n&&l("deactivate",a(n,t)),n=o[e],l("activate",a(n,t)))},d=function(e,t){var r=o.indexOf(n)+e;l(e>0?"next":"prev",a(n,t))&&c(r,t)},u={off:s,on:function(e,t){return(i[e]||(i[e]=[])).push(t),s.bind(null,e,t)},fire:l,slide:function(e,t){if(!arguments.length)return o.indexOf(n);l("slide",a(o[e],t))&&c(e,t)},next:d.bind(null,1),prev:d.bind(null,-1),parent:r,slides:o,destroy:function(e){l("destroy",a(n,e)),i={}}};return(t||[]).forEach((function(e){e(u)})),n||c(0),u}},n=e(t);const r=document.body,o=(...e)=>history.replaceState(...e),i="presenter",a="next",s=["",i,a],l="bespoke-marp-",c=`data-${l}`,d=(e,{protocol:t,host:n,pathname:r,hash:o}=location)=>{const i=e.toString();return`${t}//${n}${r}${i?"?":""}${i}${o}`},u=()=>r.dataset.bespokeView,f=e=>new URLSearchParams(location.search).get(e),m=(e,t={})=>{var n;const r={location,setter:o,...t},i=new URLSearchParams(r.location.search);for(const t of Object.keys(e)){const n=e[t];"string"==typeof n?i.set(t,n):i.delete(t)}try{r.setter({...null!==(n=window.history.state)&&void 0!==n?n:{}},"",d(i,r.location))}catch(e){console.error(e)}},g=(()=>{const e="bespoke-marp";try{return localStorage.setItem(e,e),localStorage.removeItem(e),!0}catch(e){return!1}})(),p=e=>{try{return localStorage.getItem(e)}catch(e){return null}},v=(e,t)=>{try{return localStorage.setItem(e,t),!0}catch(e){return!1}},h=e=>{try{return localStorage.removeItem(e),!0}catch(e){return!1}},y=(e,t)=>{const n="aria-hidden";t?e.setAttribute(n,"true"):e.removeAttribute(n)},b=e=>{e.parent.classList.add(`${l}parent`),e.slides.forEach((e=>e.classList.add(`${l}slide`))),e.on("activate",(t=>{const n=`${l}active`,r=t.slide,o=r.classList,i=!o.contains(n);if(e.slides.forEach((e=>{e.classList.remove(n),y(e,!0)})),o.add(n),y(r,!1),i){const e=`${n}-ready`;o.add(e),document.body.clientHeight,o.remove(e)}}))},w=e=>{let t=0,n=0;Object.defineProperty(e,"fragments",{enumerable:!0,value:e.slides.map((e=>[null,...e.querySelectorAll("[data-marpit-fragment]")]))});const r=r=>void 0!==e.fragments[t][n+r],o=(r,o)=>{t=r,n=o,e.fragments.forEach(((e,t)=>{e.forEach(((e,n)=>{if(null==e)return;const i=t<r||t===r&&n<=o;e.setAttribute(`${c}fragment`,(i?"":"in")+"active");const a=`${c}current-fragment`;t===r&&n===o?e.setAttribute(a,"current"):e.removeAttribute(a)}))})),e.fragmentIndex=o;const i={slide:e.slides[r],index:r,fragments:e.fragments[r],fragmentIndex:o};e.fire("fragment",i)};e.on("next",(({fragment:i=!0})=>{if(i){if(r(1))return o(t,n+1),!1;const i=t+1;e.fragments[i]&&o(i,0)}else{const r=e.fragments[t].length;if(n+1<r)return o(t,r-1),!1;const i=e.fragments[t+1];i&&o(t+1,i.length-1)}})),e.on("prev",(({fragment:i=!0})=>{if(r(-1)&&i)return o(t,n-1),!1;const a=t-1;e.fragments[a]&&o(a,e.fragments[a].length-1)})),e.on("slide",(({index:t,fragment:n})=>{let r=0;if(void 0!==n){const o=e.fragments[t];if(o){const{length:e}=o;r=-1===n?e-1:Math.min(Math.max(n,0),e-1)}}o(t,r)})),o(0,0)},x=document,k=()=>!(!x.fullscreenEnabled&&!x.webkitFullscreenEnabled),$=()=>!(!x.fullscreenElement&&!x.webkitFullscreenElement),E=e=>{e.fullscreen=()=>{k()&&(async()=>{return $()?null===(e=x.exitFullscreen||x.webkitExitFullscreen)||void 0===e?void 0:e.call(x):((e=x.body)=>{var t;return null===(t=e.requestFullscreen||e.webkitRequestFullscreen)||void 0===t?void 0:t.call(e)})();var e})()},document.addEventListener("keydown",(t=>{"f"!==t.key&&"F11"!==t.key||t.altKey||t.ctrlKey||t.metaKey||!k()||(e.fullscreen(),t.preventDefault())}))},L=`${l}inactive`,S=(e=2e3)=>({parent:t,fire:n})=>{const r=t.classList,o=e=>n(`marp-${e?"":"in"}active`);let i;const a=()=>{i&&clearTimeout(i),i=setTimeout((()=>{r.add(L),o()}),e),r.contains(L)&&(r.remove(L),o(!0))};for(const e of["mousedown","mousemove","touchend"])document.addEventListener(e,a);setTimeout(a,0)},P=["AUDIO","BUTTON","INPUT","SELECT","TEXTAREA","VIDEO"],_=e=>{e.parent.addEventListener("keydown",(e=>{if(!e.target)return;const t=e.target;(P.includes(t.nodeName)||"true"===t.contentEditable)&&e.stopPropagation()}))},T=e=>{window.addEventListener("load",(()=>{for(const t of e.slides){const e=t.querySelector("marp-auto-scaling, [data-auto-scaling], [data-marp-fitting]");t.setAttribute(`${c}load`,e?"":"hideable")}}))},I=({interval:e=250}={})=>t=>{document.addEventListener("keydown",(e=>{if(" "===e.key&&e.shiftKey)t.prev();else if("ArrowLeft"===e.key||"ArrowUp"===e.key||"PageUp"===e.key)t.prev({fragment:!e.shiftKey});else if(" "!==e.key||e.shiftKey)if("ArrowRight"===e.key||"ArrowDown"===e.key||"PageDown"===e.key)t.next({fragment:!e.shiftKey});else if("End"===e.key)t.slide(t.slides.length-1,{fragment:-1});else{if("Home"!==e.key)return;t.slide(0)}else t.next();e.preventDefault()}));let n,r,o=0;t.parent.addEventListener("wheel",(i=>{let a=!1;const s=(e,t)=>{e&&(a=a||((e,t)=>((e,t)=>{const n="X"===t?"Width":"Height";return e[`client${n}`]<e[`scroll${n}`]})(e,t)&&((e,t)=>{const{overflow:n}=e,r=e[`overflow${t}`];return"auto"===n||"scroll"===n||"auto"===r||"scroll"===r})(getComputedStyle(e),t))(e,t)),(null==e?void 0:e.parentElement)&&s(e.parentElement,t)};if(0!==i.deltaX&&s(i.target,"X"),0!==i.deltaY&&s(i.target,"Y"),a)return;i.preventDefault();const l=Math.sqrt(i.deltaX**2+i.deltaY**2);if(void 0!==i.wheelDelta){if(void 0===i.webkitForce&&Math.abs(i.wheelDelta)<40)return;if(i.deltaMode===i.DOM_DELTA_PIXEL&&l<4)return}else if(i.deltaMode===i.DOM_DELTA_PIXEL&&l<12)return;r&&clearTimeout(r),r=setTimeout((()=>{n=0}),e);const c=Date.now()-o<e,d=l<=n;if(n=l,c||d)return;let u;(i.deltaX>0||i.deltaY>0)&&(u="next"),(i.deltaX<0||i.deltaY<0)&&(u="prev"),u&&(t[u](),o=Date.now())}))},M=(e=`.${l}osc`)=>{const t=document.querySelector(e);if(!t)return()=>{};const n=(e,n)=>{t.querySelectorAll(`[${c}osc=${JSON.stringify(e)}]`).forEach(n)};return k()||n("fullscreen",(e=>e.style.display="none")),g||n("presenter",(e=>{e.disabled=!0,e.title="Presenter view is disabled due to restricted localStorage."})),e=>{t.addEventListener("click",(t=>{if(t.target instanceof HTMLElement){const{bespokeMarpOsc:n}=t.target.dataset;n&&t.target.blur();const r={fragment:!t.shiftKey};"next"===n?e.next(r):"prev"===n?e.prev(r):"fullscreen"===n?null==e||e.fullscreen():"presenter"===n&&e.openPresenterView()}})),e.parent.appendChild(t),e.on("activate",(({index:t})=>{n("page",(n=>n.textContent=`Page ${t+1} of ${e.slides.length}`))})),e.on("fragment",(({index:t,fragments:r,fragmentIndex:o})=>{n("prev",(e=>e.disabled=0===t&&0===o)),n("next",(n=>n.disabled=t===e.slides.length-1&&o===r.length-1))})),e.on("marp-active",(()=>y(t,!1))),e.on("marp-inactive",(()=>y(t,!0))),k()&&(e=>{for(const t of["","webkit"])x.addEventListener(t+"fullscreenchange",e)})((()=>n("fullscreen",(e=>e.classList.toggle("exit",k()&&$())))))}},O=e=>{window.addEventListener("message",(t=>{if(t.origin!==window.origin)return;const[n,r]=t.data.split(":");if("navigate"===n){const[t,n]=r.split(",");let o=Number.parseInt(t,10),i=Number.parseInt(n,10)+1;i>=e.fragments[o].length&&(o+=1,i=0),e.slide(o,{fragment:i})}}))};var A=["area","base","br","col","command","embed","hr","img","input","keygen","link","meta","param","source","track","wbr"];let C=e=>String(e).replace(/[&<>"']/g,(e=>`&${D[e]};`)),D={"&":"amp","<":"lt",">":"gt",'"':"quot","'":"apos"},N="dangerouslySetInnerHTML",B={className:"class",htmlFor:"for"},q={};function K(e,t){let n=[],r="";t=t||{};for(let e=arguments.length;e-- >2;)n.push(arguments[e]);if("function"==typeof e)return t.children=n.reverse(),e(t);if(e){if(r+="<"+e,t)for(let e in t)!1!==t[e]&&null!=t[e]&&e!==N&&(r+=` ${B[e]?B[e]:C(e)}="${C(t[e])}"`);r+=">"}if(-1===A.indexOf(e)){if(t[N])r+=t[N].__html;else for(;n.length;){let e=n.pop();if(e)if(e.pop)for(let t=e.length;t--;)n.push(e[t]);else r+=!0===q[e]?e:C(e)}r+=e?`</${e}>`:""}return q[r]=!0,r}const j=({children:e})=>K(null,null,...e),F=`${l}presenter-`,V={container:`${F}container`,dragbar:`${F}dragbar-container`,next:`${F}next`,nextContainer:`${F}next-container`,noteContainer:`${F}note-container`,noteWrapper:`${F}note-wrapper`,noteButtons:`${F}note-buttons`,infoContainer:`${F}info-container`,infoPage:`${F}info-page`,infoPageText:`${F}info-page-text`,infoPagePrev:`${F}info-page-prev`,infoPageNext:`${F}info-page-next`,noteButtonsBigger:`${F}note-bigger`,noteButtonsSmaller:`${F}note-smaller`,infoTime:`${F}info-time`,infoTimer:`${F}info-timer`},U=e=>{const{title:t}=document;document.title="[Presenter view]"+(t?` - ${t}`:"");const n={},r=e=>(n[e]=n[e]||document.querySelector(`.${e}`),n[e]);document.body.appendChild((e=>{const t=document.createElement("div");return t.className=V.container,t.appendChild(e),t.insertAdjacentHTML("beforeend",K(j,null,K("div",{class:V.nextContainer},K("iframe",{class:V.next,src:"?view=next"})),K("div",{class:V.dragbar}),K("div",{class:V.noteContainer},K("div",{class:V.noteWrapper}),K("div",{class:V.noteButtons},K("button",{class:V.noteButtonsSmaller,tabindex:"-1",title:"Smaller notes font size"},"Smaller notes font size"),K("button",{class:V.noteButtonsBigger,tabindex:"-1",title:"Bigger notes font size"},"Bigger notes font size"))),K("div",{class:V.infoContainer},K("div",{class:V.infoPage},K("button",{class:V.infoPagePrev,tabindex:"-1",title:"Previous"},"Previous"),K("span",{class:V.infoPageText}),K("button",{class:V.infoPageNext,tabindex:"-1",title:"Next"},"Next")),K("time",{class:V.infoTime,title:"Current time"}),K("time",{class:V.infoTimer,title:"Timer"})))),t})(e.parent)),(e=>{let t=!1;r(V.dragbar).addEventListener("mousedown",(()=>{t=!0,r(V.dragbar).classList.add("active")})),window.addEventListener("mouseup",(()=>{t=!1,r(V.dragbar).classList.remove("active")})),window.addEventListener("mousemove",(e=>{if(!t)return;const n=e.clientX/document.documentElement.clientWidth*100;r(V.container).style.setProperty("--bespoke-marp-presenter-split-ratio",`${Math.max(0,Math.min(100,n))}%`)})),r(V.nextContainer).addEventListener("click",(()=>e.next()));const n=r(V.next),o=(i=n,(e,t)=>{var n;return null===(n=i.contentWindow)||void 0===n?void 0:n.postMessage(`navigate:${e},${t}`,"null"===window.origin?"*":window.origin)});var i;n.addEventListener("load",(()=>{r(V.nextContainer).classList.add("active"),o(e.slide(),e.fragmentIndex),e.on("fragment",(({index:e,fragmentIndex:t})=>o(e,t)))}));const a=document.querySelectorAll(".bespoke-marp-note");a.forEach((e=>{e.addEventListener("keydown",(e=>e.stopPropagation())),r(V.noteWrapper).appendChild(e)})),e.on("activate",(()=>a.forEach((t=>t.classList.toggle("active",t.dataset.index==e.slide())))));let s=0;const l=e=>{s=Math.max(-5,s+e),r(V.noteContainer).style.setProperty("--bespoke-marp-note-font-scale",(1.2**s).toFixed(4))},c=()=>l(1),d=()=>l(-1),u=r(V.noteButtonsBigger),f=r(V.noteButtonsSmaller);u.addEventListener("click",(()=>{u.blur(),c()})),f.addEventListener("click",(()=>{f.blur(),d()})),document.addEventListener("keydown",(e=>{"+"===e.key&&c(),"-"===e.key&&d()}),!0),e.on("activate",(({index:t})=>{r(V.infoPageText).textContent=`${t+1} / ${e.slides.length}`}));const m=r(V.infoPagePrev),g=r(V.infoPageNext);m.addEventListener("click",(t=>{m.blur(),e.prev({fragment:!t.shiftKey})})),g.addEventListener("click",(t=>{g.blur(),e.next({fragment:!t.shiftKey})})),e.on("fragment",(({index:t,fragments:n,fragmentIndex:r})=>{m.disabled=0===t&&0===r,g.disabled=t===e.slides.length-1&&r===n.length-1}));let p=new Date;const v=()=>{const e=new Date,t=e=>`${Math.floor(e)}`.padStart(2,"0"),n=e.getTime()-p.getTime(),o=t(n/1e3%60),i=t(n/1e3/60%60),a=t(n/36e5%24);r(V.infoTime).textContent=e.toLocaleTimeString(),r(V.infoTimer).textContent=`${a}:${i}:${o}`};v(),setInterval(v,250),r(V.infoTimer).addEventListener("click",(()=>{p=new Date}))})(e)},X=e=>{if(!(e=>e.syncKey&&"string"==typeof e.syncKey)(e))throw new Error("The current instance of Bespoke.js is invalid for Marp bespoke presenter plugin.");Object.defineProperties(e,{openPresenterView:{enumerable:!0,value:H},presenterUrl:{enumerable:!0,get:R}}),g&&document.addEventListener("keydown",(t=>{"p"!==t.key||t.altKey||t.ctrlKey||t.metaKey||(t.preventDefault(),e.openPresenterView())}))};function H(){const{max:e,floor:t}=Math,n=e(t(.85*window.innerWidth),640),r=e(t(.85*window.innerHeight),360);return window.open(this.presenterUrl,F+this.syncKey,`width=${n},height=${r},menubar=no,toolbar=no`)}function R(){const e=new URLSearchParams(location.search);return e.set("view","presenter"),e.set("sync",this.syncKey),d(e)}const W=e=>{const t=u();return t===a&&e.appendChild(document.createElement("span")),{"":X,[i]:U,[a]:O}[t]},J=e=>{e.on("activate",(t=>{document.querySelectorAll(".bespoke-progress-parent > .bespoke-progress-bar").forEach((n=>{n.style.flexBasis=100*t.index/(e.slides.length-1)+"%"}))}))},Y=e=>{const t=Number.parseInt(e,10);return Number.isNaN(t)?null:t},z=(e={})=>{const t={history:!0,...e};return e=>{let n=!0;const r=e=>{const t=n;try{return n=!0,e()}finally{n=t}},o=(t={fragment:!0})=>{let n=t.fragment?Y(f("f")||""):null;((t,n)=>{const{min:r,max:o}=Math,{fragments:i,slides:a}=e,s=o(0,r(t,a.length-1)),l=o(0,r(n||0,i[s].length-1));s===e.slide()&&l===e.fragmentIndex||e.slide(s,{fragment:l})})((()=>{var t,r;if(location.hash){const[o]=location.hash.slice(1).split(":~:");if(/^\d+$/.test(o))return(null!==(t=Y(o))&&void 0!==t?t:1)-1;const i=document.getElementById(o)||document.querySelector(`a[name="${CSS.escape(o)}"]`);if(i){const{length:t}=e.slides;for(let o=0;o<t;o+=1)if(e.slides[o].contains(i)){const t=null===(r=e.fragments)||void 0===r?void 0:r[o],a=i.closest("[data-marpit-fragment]");if(t&&a){const e=t.indexOf(a);e>=0&&(n=e)}return o}}}return 0})(),n)};e.on("fragment",(({index:e,fragmentIndex:r})=>{n||m({f:0===r||r.toString()},{location:{...location,hash:`#${e+1}`},setter:(...e)=>t.history?history.pushState(...e):history.replaceState(...e)})})),setTimeout((()=>{o(),window.addEventListener("hashchange",(()=>r((()=>{o({fragment:!1}),m({f:void 0})})))),window.addEventListener("popstate",(()=>{n||r((()=>o()))})),n=!1}),0)}},G=(e={})=>{var t;const n=e.key||(null===(t=window.history.state)||void 0===t?void 0:t.marpBespokeSyncKey)||Math.random().toString(36).slice(2),r=`bespoke-marp-sync-${n}`;var i;i={marpBespokeSyncKey:n},m({},{setter:(e,...t)=>o({...e,...i},...t)});const a=()=>{const e=p(r);return e?JSON.parse(e):Object.create(null)},s=e=>{const t=a(),n={...t,...e(t)};return v(r,JSON.stringify(n)),n},l=()=>{window.removeEventListener("pageshow",l),s((e=>({reference:(e.reference||0)+1})))};return e=>{l(),Object.defineProperty(e,"syncKey",{value:n,enumerable:!0});let t=!0;setTimeout((()=>{e.on("fragment",(e=>{t&&s((()=>({index:e.index,fragmentIndex:e.fragmentIndex})))}))}),0),window.addEventListener("storage",(n=>{if(n.key===r&&n.oldValue&&n.newValue){const r=JSON.parse(n.oldValue),o=JSON.parse(n.newValue);if(r.index!==o.index||r.fragmentIndex!==o.fragmentIndex)try{t=!1,e.slide(o.index,{fragment:o.fragmentIndex,forSync:!0})}finally{t=!0}}}));const o=()=>{const{reference:e}=a();void 0===e||e<=1?h(r):s((()=>({reference:e-1})))};window.addEventListener("pagehide",(e=>{e.persisted&&window.addEventListener("pageshow",l),o()})),e.on("destroy",o)}},{PI:Q,abs:Z,sqrt:ee,atan2:te}=Math,ne={passive:!0},re=({slope:e=-.7,swipeThreshold:t=30}={})=>n=>{let r;const o=n.parent,i=e=>{const t=o.getBoundingClientRect();return{x:e.pageX-(t.left+t.right)/2,y:e.pageY-(t.top+t.bottom)/2}};o.addEventListener("touchstart",(({touches:e})=>{r=1===e.length?i(e[0]):void 0}),ne),o.addEventListener("touchmove",(e=>{if(r)if(1===e.touches.length){e.preventDefault();const t=i(e.touches[0]),n=t.x-r.x,o=t.y-r.y;r.delta=ee(Z(n)**2+Z(o)**2),r.radian=te(n,o)}else r=void 0})),o.addEventListener("touchend",(o=>{if(r){if(r.delta&&r.delta>=t&&r.radian){const t=(r.radian-e+Q)%(2*Q)-Q;n[t<0?"next":"prev"](),o.stopPropagation()}r=void 0}}),ne)},oe=new Map;oe.clear(),oe.set("none",{backward:{both:void 0,incoming:void 0,outgoing:void 0},forward:{both:void 0,incoming:void 0,outgoing:void 0}});const ie={both:"",outgoing:"outgoing-",incoming:"incoming-"},ae={forward:"",backward:"-backward"},se=e=>`--marp-bespoke-transition-animation-${e}`,le=e=>`--marp-transition-${e}`,ce=se("name"),de=se("duration"),ue=e=>new Promise((t=>{const n={},r=document.createElement("div"),o=e=>{r.remove(),t(e)};r.addEventListener("animationstart",(()=>o(n))),Object.assign(r.style,{animationName:e,animationDuration:"1s",animationFillMode:"both",animationPlayState:"paused",position:"absolute",pointerEvents:"none"}),document.body.appendChild(r);const i=getComputedStyle(r).getPropertyValue(le("duration"));i&&(n.defaultDuration=i),((e,t)=>{requestAnimationFrame((()=>{e.style.animationPlayState="running",requestAnimationFrame((()=>t(void 0)))}))})(r,o)})),fe=async e=>oe.has(e)?oe.get(e):(e=>{const t={},n=[];for(const[r,o]of Object.entries(ie))for(const[i,a]of Object.entries(ae)){const s=`marp-${o}transition${a}-${e}`;n.push(ue(s).then((e=>{t[i]=t[i]||{},t[i][r]=e?{...e,name:s}:void 0})))}return Promise.all(n).then((()=>t))})(e).then((t=>(oe.set(e,t),t))),me=e=>Object.values(e).flatMap(Object.values).every((e=>!e)),ge=(e,{type:t,backward:n})=>{const r=e[n?"backward":"forward"],o=(()=>{const e=r[t],n=e=>({[ce]:e.name});if(e)return n(e);if(r.both){const e=n(r.both);return"incoming"===t&&(e[se("direction")]="reverse"),e}})();return!o&&n?ge(e,{type:t,backward:!1}):o||{[ce]:"__bespoke_marp_transition_no_animation__"}},pe=e=>{if(e)try{const t=JSON.parse(e);if((e=>{if("object"!=typeof e)return!1;const t=e;return"string"==typeof t.name&&(void 0===t.duration||"string"==typeof t.duration)})(t))return t}catch(e){}},ve="_tSId",he="_tA",ye="bespoke-marp-transition-warming-up",be=window.matchMedia("(prefers-reduced-motion: reduce)"),we="__bespoke_marp_transition_reduced_outgoing__",xe="__bespoke_marp_transition_reduced_incoming__",ke={forward:{both:void 0,incoming:{name:xe},outgoing:{name:we}},backward:{both:void 0,incoming:{name:xe},outgoing:{name:we}}},$e=e=>{if(!document.startViewTransition)return;const t=t=>(void 0!==t&&(e._tD=t),e._tD);let n;t(!1),((...e)=>{const t=[...new Set(e).values()];return Promise.all(t.map((e=>fe(e)))).then()})(...Array.from(document.querySelectorAll("section[data-transition], section[data-transition-back]")).flatMap((e=>[e.dataset.transition,e.dataset.transitionBack].flatMap((e=>{const t=pe(e);return[null==t?void 0:t.name,(null==t?void 0:t.builtinFallback)?`__builtin__${t.name}`:void 0]})).filter((e=>!!e))))).then((()=>{document.querySelectorAll("style").forEach((e=>{e.innerHTML=e.innerHTML.replace(/--marp-transition-duration:[^;}]*[;}]/g,(e=>e.slice(0,-1)+"!important"+e.slice(-1)))}))}));const r=(n,{back:r,cond:o})=>i=>{var a;const s=t();if(s)return!!i[he]||!("object"!=typeof s||(s.skipTransition(),!i.forSync));if(!o(i))return!0;const l=e.slides[e.slide()],c=()=>{var e;return null!==(e=i.back)&&void 0!==e?e:r},d="data-transition"+(c()?"-back":""),u=l.querySelector(`section[${d}]`);if(!u)return!0;const f=pe(null!==(a=u.getAttribute(d))&&void 0!==a?a:void 0);return!f||((async(e,{builtinFallback:t=!0}={})=>{let n=await fe(e);if(me(n)){if(!t)return;return n=await fe(`__builtin__${e}`),me(n)?void 0:n}return n})(f.name,{builtinFallback:f.builtinFallback}).then((e=>{if(!e){t(!0);try{n(i)}finally{t(!1)}return}let r=e;be.matches&&(console.warn("Use a constant animation to transition because preferring reduced motion by viewer has detected."),r=ke);const o=document.getElementById(ve);o&&o.remove();const a=document.createElement("style");a.id=ve,document.head.appendChild(a),((e,t)=>{const n=[`:root{${le("direction")}:${t.backward?-1:1};}`,":root:has(.bespoke-marp-inactive){cursor:none;}"],r=t=>{var n,o,i;const a=(null===(n=e[t].both)||void 0===n?void 0:n.defaultDuration)||(null===(o=e[t].outgoing)||void 0===o?void 0:o.defaultDuration)||(null===(i=e[t].incoming)||void 0===i?void 0:i.defaultDuration);return"forward"===t?a:a||r("forward")},o=t.duration||r(t.backward?"backward":"forward");void 0!==o&&n.push(`::view-transition-group(*){${de}:${o};}`);const i=e=>Object.entries(e).map((([e,t])=>`${e}:${t};`)).join("");return n.push(`::view-transition-old(root){${i(ge(e,{...t,type:"outgoing"}))}}`,`::view-transition-new(root){${i(ge(e,{...t,type:"incoming"}))}}`),n})(r,{backward:c(),duration:f.duration}).forEach((e=>{var t;return null===(t=a.sheet)||void 0===t?void 0:t.insertRule(e)}));const s=document.documentElement.classList;s.add(ye);let l=!1;const d=()=>{l||(n(i),l=!0,s.remove(ye))},u=()=>{t(!1),a.remove(),s.remove(ye)};try{t(!0);const e=document.startViewTransition(d);t(e),e.finished.finally(u)}catch(e){console.error(e),d(),u()}})),!1)};e.on("prev",r((t=>e.prev({...t,[he]:!0})),{back:!0,cond:e=>{var t;return e.index>0&&!((null===(t=e.fragment)||void 0===t||t)&&n.fragmentIndex>0)}})),e.on("next",r((t=>e.next({...t,[he]:!0})),{cond:t=>t.index+1<e.slides.length&&!(n.fragmentIndex+1<n.fragments.length)})),setTimeout((()=>{e.on("slide",r((t=>e.slide(t.index,{...t,[he]:!0})),{cond:t=>{const n=e.slide();return t.index!==n&&(t.back=t.index<n,!0)}}))}),0),e.on("fragment",(e=>{n=e}))};let Ee;const Le=()=>(void 0===Ee&&(Ee="wakeLock"in navigator&&navigator.wakeLock),Ee),Se=async()=>{const e=Le();if(e)try{return await e.request("screen")}catch(e){console.warn(e)}return null},Pe=async()=>{if(!Le())return;let e;const t=()=>{e&&"visible"===document.visibilityState&&Se()};for(const e of["visibilitychange","fullscreenchange"])document.addEventListener(e,t);return e=await Se(),e};((e=document.getElementById(":$p"))=>{(()=>{const e=f("view");r.dataset.bespokeView=e===a||e===i?e:""})();const t=(e=>{const t=f(e);return m({[e]:void 0}),t})("sync")||void 0;n.from(e,((...e)=>{const t=s.findIndex((e=>u()===e));return e.map((([e,n])=>e[t]&&n)).filter((e=>e))})([[1,1,0],G({key:t})],[[1,1,1],W(e)],[[1,1,0],_],[[1,1,1],b],[[1,0,0],S()],[[1,1,1],T],[[1,1,1],z({history:!1})],[[1,1,0],I()],[[1,1,0],E],[[1,0,0],J],[[1,1,0],re()],[[1,0,0],M()],[[1,0,0],$e],[[1,1,1],w],[[1,1,0],Pe]))})()}();</script></body></html>